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ABSTRACT 
Bis(monoacylglycero)phosphate (BMP), a Novel Macrophage Associated 
Phospholipid: Implications in Gangliosidoses and Cancer 
 
Zeynep Akgöç 
Thesis Advisor: Thomas N. Seyfried 
 
Bis(monoacylglycero)phosphate, BMP, is a negatively charged glycerol-
phospholipid with an unusual sn-1;sn-1’ structural configuration. BMP is primarily 
enriched in endosomal/lysosomal membranes.  BMP is thought to play a role in 
glycosphingolipid degradation and cholesterol transport.  It constitutes only about 
1-2% of the total phospholipids in most mammalian cells, but is abundant in lung 
alveolar macrophages where it can comprise up to 16% of the total 
phospholipids. BMP also accumulates in tissues of humans and animals with 
lysosomal storage disorders. However, little information is available on BMP 
levels in gangliosidosis brain tissue.   
 
In this work, I found that total BMP content was significantly greater in cells of 
macrophage/microglial origin than in cells of macroglial origin (astrocyte, 
oligodendrocyte progenitor), whether normal or tumorigenic. I also observed that 
BMP in brain was significantly greater in humans and in animals (mice, cats, 
American black bears) with either GM1 or GM2 ganglioside storage diseases, 
than in brains of normal subjects. Since BMP is associated with macrophages, I 
also analyzed the BMP levels in relation to disease-associated inflammation in 
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gangliosidoses. I found that BMP levels were increased due to accumulation of 
primary storage material gangliosides, rather than an outcome of disease-
associated inflammation. 
 
In addition, in this thesis I also explored the effect of new ketogenic diet formula 
from Solace Nutrition (KetoGen) on the growth and metastatic spread of the VM-
M3 tumor.  Most current drug therapies for cancer are toxic and only marginally 
effective in providing long-term management. Respiratory insufficiency with 
compensatory aerobic fermentation (Warburg effect) is the hallmark biochemical 
phenotype of nearly all neoplastic cells within tumors.  Calorie restriction, which 
lowers blood glucose and elevates ketone bodies, is known to reduce tumor 
growth to a certain extent, however it does not reduce systemic metastasis. 
Tumor bearing VM mice were fed either a standard lab chow diet in unrestricted 
amounts (SD-UR), a standard lab chow restricted to obtain an 18% reduction in 
body weight (SD-R), or the KetoGen diet restricted (KG-R) to match the body 
weights of the SD-R group.  Tumor size was significantly smaller and organ 
metastasis was significantly less in the KG-R group than in the SD-UR or SD-R 
groups.  Even though blood glucose was reduced similarly in both the SD-R and 
KG-R groups, blood ketones were 3-fold higher in the KG-R group than in the 
SD-R group.  These results show that VM-M3 tumor growth and systemic 
metastasis were managed better with the restricted KetoGen KD than with 
calorie restriction of a high carbohydrate standard diet.  As all human and mouse 
tumors cells suffer from respiratory insufficiency, my findings suggest that the 
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restricted KetoGen diet should be an effective non-toxic therapy against tumor 
growth and systemic metastatic cancer. 	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CHAPTER 1 	  
Introduction 
 
Bis(monoacylglycero)phosphate (BMP), formerly known as lysobisphosphatidic 
acid (LBPA), is a negatively charged phospholipid, localized to late endosomes 
and lysosomes [1, 2]. BMP is a structural isomer of phosphatidylglycerol (PG) 
with an unusual sn-1:sn-1’ configuration (Figure 1) [3, 4]. BMP consists of a 
phosphate bound to two glycerol groups, each with a single acyl chain [3]. 
Phosphatidylglycerol is considered the biosynthetic precursor of BMP [5]. The 
synthetic pathway is thought to involve the deacylation of PG by Phospholipase 
A2 and then transacylation, possibly using two lysoPG molecules to generate 
BMP (Figure 2) [6]. Substrates for these reactions, such as PG, do not all 
originate in the lysosome, but are rather obtained by lysosomal interaction with 
the membranes of other organelles [7]. Degradation of BMP is also unusual, as 
its rate of degradation is much slower than that of other phospholipids due to its 
unique sn-1:sn-1’ configuration [8].  However, BMP can be degraded by 
lysosomal phosphodiesterase and lysosomal phospholipase A [9].  The fatty acid 
composition is oleic acid (C18:1) and docosahexaenoic acid (C22:6n-3) in many 
cell types such as rat uterine stromal cells, rat adrenal gland PC12 cultured cells, 
rat and human liver [10-13]. In alveolar macrophages linoleic acid (C18:2) and 
arachidonic acid (C20:4) is also present in high amounts in BMP.  BMP fatty acid 
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variation might be important for the biochemical function of each particular BMP 
species [12-15]. 
BMP can have multiple functions within the endocytic pathway.  At low pH, the 
cone shape of BMP plays a role in membrane asymmetry, resulting in 
invagination and the formation of internal endosomal vesicles called intraluminal 
vesicles (ILVs) or multivesicular bodies (MVBs) [16].  As the endosome 
undergoes maturation, the inner membrane becomes enriched in BMP and the 
decreasing luminal pH induces ILV formation [17]. These vesicles increase 
storage capacity, linking BMP to the control of lysosomal cholesterol storage [18]. 
BMP is also proposed to have a role in the lysosomal degradation of 
glycosphingolipids through interactions with saposins and hydrolases (Figure 3) 
[14, 19, 20]. 
Lysosomal storage diseases (LSD) are a group of inherited disorders that are 
caused by defective/deficient lysosomal enzymes [21]. Sandhoff disease (SD) 
and GM1 gangliosidosis are caused by genetic deficiencies of lysosomal β-
hexosaminidase (Hexβ) and acid β-galactosidase (β-gal), respectively [21-25]. 
Sandhoff Disease is characterized by the storage of ganglioside GM2 and its 
asialo derivative GA2, whereas GM1 gangliosidosis involves the storage of 
ganglioside GM1 and its asialo derivative GA1 [22-25]. Elevated levels of BMP 
are observed in many lysosomal storage diseases 
including mucopolysaccharidosis, Niemann-Pick disease type A/B/C, Gaucher 
and Fabry disease [26-35]. However, this elevation is not present in all LSDs 
such as the Spielmeyer-Sjogren type of neuronal ceroid-lipofuscinosis [31]. 
	   3	  
Previous studies showed that BMP was elevated in the brain tissue of a Sandhoff 
Disease human patient, and in serum obtained from GM2 gangliosidoses 
patients [31, 36]. However, a detailed study of BMP content in the GM2 and GM1 
gangliosidoses brain is lacking [37].  We found that the levels of BMP were 
significantly higher in humans and animals with either GM1 or GM2 
gangliosidoses than in brain tissue from species matched control samples.  The 
data indicated that BMP is a secondary storage material along with gangliosides 
in the gangliosidosis brain.  	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Figure 1. Structure of 2, 2’ diacyl-sn 1: sn 1’ 
Bis(monoacylglycero)phosphate (BMP) as previously described [38]. 
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Figure 2. Proposed biosynthesis of BMP suggested by Waite group: 
Phosphatidylglycerol (PG) is hydrolyzed by Phospholipase A2 (PLA2) to form 1-
acyl-LysoPhosphaditylglycerol (LPG) (step 1). A transacylase (TA) acylate LPG, 
using a phospholipid (PL) (possibly another PG) as the acyl donor, and forms sn-
3:sn-1’ BMP (step 2). Sn-3:sn-l'-BMPglycerol backbone  is reoriented by an 
enzymatic activity (ROE), and yields sn-1:sn-1'-LPG by unknown mechanism 
(step 3). Transacylation of sn-1:sn-1'-LPG yields the final sn-1:sn-1'-BMP  (step 
4) [39]. 
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Figure 3. BMP aids the degradation of glycospingolipids with interacting 
lysosomal lipid binding proteins in Lysosomes. Cationic lysosomal lipid 
binding proteins (Saps and GM2-AP) and enzymes such as Acid Ceramidase 
and Glucocerebrosidase bind BMP containing negatively charged inner 
membranes. Lysosomal lipid binding proteins present membrane-bound lipids to 
water-soluble enzymes for degradation [8]. 
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Materials and Methods 
 
Mice 
 
VM/Dk mouse strain was obtained from G. Carlson (McLaughlin Research 
Institute, Great Falls, Montana) and from H. Fraser (University of Edinburgh, 
Scotland). The SV/129 Hexβ (+/−) mice were obtained from Dr. Richard Proia 
(NIH). β-galactosidase (+/-) mice were derived by homologous recombination 
and embryonic stem cell technology as previously described [40, 41]. 
Homozygous (-/-) mouse pups were derived from crossing heterozygous females 
with heterozygous male mice. Genotypes were determined as described 
previously [42, 43]. Cortex brain samples were collected at humane end point 
and stored at -80 °C. Humane end point for Hexβ (-/-) mice (Sandhoff Disease) 
was about 100 days and for β-gal (-/-) (GM1 gangliosidosis) mice was about 180 
days. All mice were propagated in the Boston College Animal Care Facility and 
were housed in plastic cages with filter tops containing Sani-Chip bedding (P. J. 
Murphy Forest Products Corp.; Montville, NJ). The room was maintained at 22°C 
on a 12 hour light/12 hour dark cycle. Food (PROLAB R/M/H/3000 Lab Chow; 
Agway, St. Louis, MO) and water were provided ad libitum.  All animal 
experiments were carried out with ethical committee approval in accordance with 
the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals and were approved by the Institutional Animal Care Committee. 
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Cats  
 
Sandhoff Disease and GM1 cats were obtained from the Baker colony at Auburn 
University, AL and result from naturally occurring mutations as previously 
described [44-49]. Sandhoff Disease cats had <3% normal hexosaminidase 
activity in cerebral cortex [50]. GM1 cats had <10% of β-galactosidase activity. 
Both feline models showed stereotypical clinical disease progression including 
corresponding ganglioside storage (GM2 for Sandhoff Disease, and GM1 for 
GM1 cats). Feline models also showed all brain and peripheral organ pathologies 
of the ganglioside disease and represented an authentic model to study disease 
progression [45, 51]. According to the recommendations of the AVMA Panel on 
Euthanasia, animals were euthanized by pentobarbital overdose, followed by 
transcardial perfusion with heparinized, cold saline (0.9 % NaCl) until jugular 
perfusate was clear. Cerebral cortex samples were collected at humane endpoint 
from gangliosidosis cats (Sandhoff Disease, 4-5 months; GM1, 7-8 months) and 
from age matched normal cats. Samples were frozen in liquid nitrogen and 
stored at -80°C. The Auburn University Institutional Animal Care and Use 
Committee approved all performed animal procedures. 
 
 
Bears 
 
American black bears with GM1 gangliosidosis were found in Northeast United 
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States. The bears were in poor clinical condition at 10-14 months in age and 
humanely euthanized as previously described [52]. The bear brain tissue was 
obtained as a gift from Joseph Alroy, Tufts University, Boston MA. 
 
Human  
 
Sandhoff Disease human cortex sample and its age-matched control were 
obtained from the NICHD Brain and Tissue Bank for Developmental Disorders at 
the University of Maryland, Baltimore. 
 
Lipid isolation, purification, and quantification 
 
Total lipid extraction 	  
Total lipids were extracted from the cortexes of lyophilized whole brain or 
microsomal fractions with chloroform and methanol 1:1 by volume. Samples were 
further purified and prepared for column chromatography using previously 
described procedures [53, 54]. 
 
Column Chromatography 	  
DEAE-Sephadex (A-25, Pharmacia Biotech, Uppsala, Sweden) columns were 
used to separate neutral and acidic lipids [55]. Total lipid extract was applied to 
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DEAE-Sephadex column that was equilibrated in solvent A 
(chloroform:methanol:water 30:60:8;v/v/v). Neutral lipids were eluted with solvent 
A. Acidic lipids, including gangliosides, were eluted with solvent B, comprised of 
chloroform:methanol: 0.8 M Na acetate (30:60:8 ; v/v/v)  
 
Ganglioside purification 	  
Acidic lipids were dried by rotary evaporation and further separated to acidic lipid 
and ganglioside fractions by Folch partitioning, as previously described [54, 56]. 
An aliquot was taken from ganglioside fraction for sialic acid determination and 
sialic acid was quantified by resorcinol assay. Gangliosides were further purified 
with base treatment and desalting as previously described [23, 24, 54].  
Treatment of gangliosides with mild base is needed to remove contaminating 
phospholipids and any ganglioside internal esters or salt forms that might arise 
as artifacts of the lipid isolation procedures [57, 58].  
BMP purification 	  
After Folch partitioning, the lower phase including the acidic phospholipid 
fraction, was dried under nitrogen and resuspended in 10 mL of chloroform: 
methanol (1:1 by volume). This fraction was composed of 
bis(monoacylglycero)phosphate, cardiolipin, sulfatides, phosphatidyglycerol, 
phosphatidylserine, phosphatidylinositol and phosphatidic acid. High-
performance thin-layer chromatography (HPTLC) was used to separate and 
visualize BMP.  No BMP was detected in the Folch upper phase indicating that 
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all BMP partitioned into the lower phase. 
 
High-performance thin-layer chromatography 	  
High-performance thin-layer chromatography (HPTLC) was used to separate and 
visualize acidic and neutral lipids as previously described [23, 54, 59] 
Bis(monoacylglycero)phosphate was purchased from Avanti Polar Lipids 
(Alabaster, AL, USA). Lipid standards were either purchased from Matreya Inc. 
(Pleasant Gap, PA, USA), Sigma (St. Louis, MO, USA), or were provided by Dr. 
Robert Yu (Medical College of Georgia, Augusta, GA, USA). For BMP 
visualization, plates were subjected to a single ascending run with chloroform: 
methanol: ammonium hydroxide (30% by volume) (65:35:5/v:v:v) for 5 minutes 
and visualized by charring with 3% cupric acetate in 8% phosphoric acid solution, 
followed by heating in an oven at 165°C for 7 minutes. A Personal Densitometer 
SI determined densities of individual bands with ImageQuant software (Molecular 
Dynamics; Sunnyvale, CA). Concentrations of individual lipids were calculated 
based on standard curve obtained by standard lanes on HPTLC. 
 
The amount of gangliosides spotted per lane was equivalent to 1.5 µg of sialic 
acid. Gangliosides were separated by a solution of chloroform:methanol:CaCl2 
(0.02%) (55:45:10; v/v/v) and visualized by spraying the dried plates with the 
resorcinol reagent, followed by heating at 95°C. Following quantification of 
ganglioside bands, total brain gangliosides were normalized to 100%, and sialic 
acid values were quantified by percent distribution of each ganglioside band [60].  
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Sialic acid quantification 	  
Folch upper phase including ganglioside fraction was desalted and amount of 
sialic acid was measured before and after desalting by the resorcinol assay as 
previously described. [24, 50]. Three aliquots of each ganglioside sample were 
dried under vacuum. A resorcinol: dH2O, 1:1, v/v solution (resorcinol reagent-
HCl: 0.2 M resorcinol: dH2O: 0.1 M CuSO4, 40: 5: 5: 0.125, v/v/v/v) was added to 
each sample, followed by submersion in a boiling water bath for 17 min. After 
cooling on ice, the reaction was stopped with butyl acetate-N-butanol, 85:15, v/v. 
Each sample was vortexed and centrifuged at 700 g for 2 min. The absorbance 
of the upper aqueous layer was recorded at 580 nm using a Shimadzu UV-1601 
spectrophotometer (Shimadzu; Torrance, CA). Sialic acid values were fit to a 
standard curve using N-acetylneuraminic acid as a standard [61]. 
Gas chromatography 
 
Preparative HPTLC was used to separate BMP with chloroform: methanol: 
ammonium hydroxide (30% by volume) (65:35:5/v:v:v).  Lipids were detected 
after spraying HPTLC with acetone:water (80:20) containing 5% primulin.  The 
BMP fraction was scraped from the plate and esterified with acetyl 
chloride:methanol (1:4 volume/volume), and neutralized with K2CO3 (4%) in a 
sealed borosilicate tube under nitrogen. Separation of fatty acid methyl esters 
was carried out using gas-liquid chromatography (HP 6890) using a 30m x 
0.25mm x 0.25µm Omegawax 250 fused silica capillary column (Supelco). Area 
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under the curve values used to calculate the percentages of individual fatty acids 
compared to sum area of all fatty acids. 
 
Mass spectrometry 
 
Preparative HPTLC, using the solvent system chloroform:methanol:ammonia 
(65:35:5/v:v:v), was used to separate BMP from other phosphoglycerides.  
Shotgun lipidomics analyses of BMP was performed on a triple-stage quadrupole 
(QqQ) mass spectrometer (Thermo Scientific, San Jose, CA) equipped with an 
ionspray ion source as previously described [62]. 
AAV vector design, preparation and delivery to brain 
 
The following vectors were used in this study: AAV1-CBA-Hexα, and AAV1-CBA-
Hexβ. AAV vectors encoding alpha- or beta-subunits of human β-
hexosaminidase were constructed by PCR amplification of the respective cDNAs 
in the Mammalian Gene Collection (MGC) clones 14125 (IMAGE 3353424; 
Genbank: BC018927), and 1725 (IMAGE: 2967035; Genbank: BC017378) 
obtained from the American Type Culture Collection (Manassas, VA). The 
primers used for PCR amplification were: 
HexA-1: ATCCACTAGTGGAGCACCATGACAAGTTCCAGGCTTTGGT; 
HexA-2: AATTCTCGAGTCAGGTCTGTTCAAACTCCTGCTCAC; 
HexB-1: ATCCACTAGTGGAGCACCATGGAGCTGTGCGGGCTGG; 
HexB-2: AATTCTCGAGTTACATGTTCTCATGGTTACAATATC.  
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PCR products were digested with Spe I and Xho I (sequences underlined in the 
primers above) and cloned into pAAV-CBA-MBG-W [63] in place of the mouse 
βgal cDNA. All vectors used in this study carry the woodchuck hepatitis virus 
post-transcriptional regulatory element (WPRE). AAV1 vector stocks were 
produced as described [63]. 
Six week-old Sandhoff Disease mice were injected with 2 µl of 1:1 formulation of 
AAV1-CBA-Hexα  + AAV1-CBA-Hex β vectors (7.2x1012 gc/ml for each vector in 
the formulation) stereotaxically into left and right thalamus (n=4) (Coordinates 
from bregma in mm: AP –2.0, ML ±1.5, DV –2.5) at a rate of 0.2. µl.min-1 as 
previously described [64]. 
 
Statistical analysis 
 
Statistical significance of data was analyzed by the two-tailed Student’s t-Test 
between the normal and the diseased samples. Interquartile range was 
approximated between the maximum and minimum elements in the data set 
divided by 2. 
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Results  	  
BMP accumulates in brain of mice, cat, bear, and human with GM2 
(Sandhoff Disease) or GM1 gangliosidoses  
 
Our objective was to evaluate the content and fatty acid composition of BMP in 
the brain of mice, cats, bear, and humans with GM2 (Sandhoff Disease) and/or 
GM1 gangliosidosis. BMP accumulation (up to 32-fold increase) was found in all 
samples of gangliosidosis brain tissue (Figure 4, Table 1), showing that BMP 
accumulates as a secondary storage material in the gangliosidosis brain. BMP 
levels were also higher in juvenile (p15) β-gal (-/-) (GM1 gangliosidosis) mouse 
brains than in age-matched β-gal (+/-) (normal) brains (Figure 5).  
 
BMP accumulates in liver of GM2 (Sandhoff Disease) mice but not in liver 
of GM1 gangliosidosis mice 
 
We also observed BMP was stored in the liver of Hexβ (-/-) (Sandhoff Disease 
mice), but not in the liver of β-gal (-/-) GM1 gangliosidosis mice (Figure 6A, Table 
1). BMP accumulations were in line with GM2 ganglioside storage seen in 
Sandhoff Disease mice liver There is no GM1 accumulation in GM1 
gangliosidosis mice liver due to absence of GM1 synthesis in liver (Figure 6B) 
[65]. 
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Effect of LPS injections on BMP content in Sandhoff Disease mice brain. 
 
We analyzed whether further inducing inflammation with LPS could increase 
BMP levels in Sandhoff Disease mice brain.  Sandhoff Disease mice received 4 
daily injections of 1mg/kg i.p LPS injections to induce microglia inflammation. 
BMP content was similar in Sandhoff Disease mouse brain injected with LPS or 
saline (PBS) for 4 consecutive days suggesting increasing inflammation in 
Sandhoff Disease brain didn’t contribute further to already existing BMP levels in 
Sandhoff Disease mice brain (Figure 7). 
 
	  
BMP separates from its structural isomer PG by HPTLC and Mass 
Spectrometry 	  
BMP has the same molecular weight with phosphatidylglycerol (PG), therefore it 
is challenging to separate BMP from PG in mass spectrometry without an initial 
chromatography procedure. In our solvent system BMP (Rf =0.71), separated 
from PG (Rf=0.57) clearly. In order to further validate BMP as a separate lipid 
from PG, we analyzed the isolated BMP from HPTLC plates by a triple-stage 
quadrupole (QqQ) mass spectrometer. Analysis of commercial standards from 
Avanti showed BMP to have a distinct peak around m/z 92, while PG standard 
had two distinct peaks at m/z 171 and m/z 227. The BMP isolated from GM2 
gangliosidosis mice brain also showed the distinct peak at m/z 92, while these 
samples had very low peaks at m/z 171 and m/z 227 (Figure 8). Also the 
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predominant BMP species in GM2 gangliosidosis mice had molecular weight of 
865.5 corresponding to 22:6- 22:6 BMP (Figure 8), which correlates well with the 
gas chromatography data showing that 22:6 is the predominant BMP fatty acid 
species in mice with GM2 gangliosidosis.  
 
Fatty acyl species of BMP 
 
We analyzed the fatty acyl species of BMP by gas chromatography. Major fatty 
acid species in BMP from gangliosidoses brain samples included stearic acid 
(C18:0), oleic acid (C18:1), arachidonic acid (20:4) and docosahexaenoic acid 
(22:6) (Table 2). C22:6 was the predominant (57-62%) fatty acid present in brain 
of GM1 and GM2 gangliosidoses mice and in GM1 gangliosidosis American 
black bear. These species contained 16-22 % of C18:0 and C18:1. In contrast, 
C18:0 + C18:1 were the predominant (37-57%) fatty acids in brain of GM1 and 
GM2 gangliosidosis cats and GM2 gangliosidosis human. These species had 
lower amounts (17-37%) of C22:6 (Table 2). 
 
AAV-mediated gene therapy reduces storage of brain BMP and ganglioside 
content 
 
The relationship of BMP storage to ganglioside storage was evaluated in brains 
of Hexβ (+/-) (normal), Hexβ (-/-) (Sandhoff Disease) mice that were treated or 
not treated with AAV gene therapy.  Both GM2 and BMP levels were lower in the 
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AAV-treated Sandhoff Disease mice than in the untreated Sandhoff Disease 
mice (Table 3). GM2 content was significantly correlated with the BMP content in 
these 13 brain samples analyzed (r = 0.9822, P< 0.01). For the correlation 
analysis, an arbitrary value of 0.5 µg sialic acid/ 100 mg of tissue dry weight was 
used to represent 0 amounts on the HPTLC plate.  
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Figure 4. HPTLC analysis of acidic lipids in the brains of mice, cats, 
humans, and bear with ganglioside storage disease.  The normal (N), 
Sandhoff Disease and GM1 mice represent the Hexβ (+/-), Hexβ (-/-) and β-gal (-
/-) mice, respectively. The HPTLC was developed for 5 min with chloroform: 
methanol: ammonia (30% aqueous solution) (65:35:5; v/v/v). The amount of 
acidic lipid spotted per lane was equivalent to 200 µg of tissue dry weight. The 
bands were visualized by charring with 3 % cupric acetate in 8 % phosphoric acid 
solution. Std Standard is a mixture of purified acidic lipids including BMP 
Bis(monoacylglycero)phosphate; CL cardiolipin; PA phosphatidic acid; Sulf 
sulfatides; PS phosphatidylserine  and PI phosphatidylinositol.  
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Figure 5. BMP content in the brains of juvenile (p15) or adult (p100) mice 
with ganglioside storage disease.  The normal (N), GM1 gangliosidosis mice 
represent the β-gal (+/-), β-gal (-/-) mice, respectively. The HPTLC was 
developed for 5 min with chloroform: methanol: ammonia (30% aqueous solution) 
(65:35:5; v/v/v). The amount of acidic lipid spotted per lane was equivalent to 200 
µg of tissue dry weight. The bands were visualized by charring with 3 % cupric 
acetate in 8 % phosphoric acid solution. BMP accumulation was observed in 
Juvenile p15 mice as well as adult P100 mice. Std Standard is a mixture of 
purified acidic lipids including BMP Bis(monoacylglycero)phosphate; CL 
cardiolipin; PA phosphatidic acid; Sulf sulfatides; PS phosphatidylserine  and PI 
phosphatidylinositol.  	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Figure 6. BMP and Ganglioside levels in livers of GM1 Gangliosidosis and 
Sandhoff Disease mice. (A) HPTLC analysis of acidic lipids in the livers of mice 
with ganglioside storage disease. The normal (N), Sandhoff Disease and GM1 
mice represent the 100 days old Hexβ (+/-), 100 days old Hexβ (-/-) and 180 
days old β-gal (-/-) mice, respectively. The HPTLC was developed for 5 min with 
chloroform: methanol: ammonia (30% aqueous solution) (65:35:5; v/v/v). The 
amount of acidic lipid spotted per lane was equivalent to 200 µg of tissue dry 
weight. The bands were visualized by charring with 3 % cupric acetate in 8 % 
phosphoric acid solution. Std Standard is a mixture of purified acidic lipids 
including BMP Bis(monoacylglycero)phosphate; CL cardiolipin; PA phosphatidic 
acid; Sulf sulfatides; PS phosphatidylserine  and PI phosphatidylinositol. (B) 
Ganglioside distribution in the livers of mice with ganglioside storage disease. 
The amount of ganglioside sialic acid spotted per lane was equivalent to 1.5 µg 
sialic acid. The plate was developed in a single ascending run (90 min) with 
chloroform: methanol: water (55:45:10 v/v/v) containing 0.02% calcium chloride. 
The bands were visualized by spraying with the resorcinol reagent and heating to 
95°C. 	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Figure 7. Effect of LPS on BMP content in Sandhoff Disease mouse brain. 
Sandhoff Disease mice received 4 daily injections of 1mg/kg i.p LPS injections.  
BMP content was analyzed with HPTLC of acidic lipids. The HPTLC was 
developed for 5 min with chloroform: methanol: ammonia (30% aqueous solution) 
(65:35:5; v/v/v). The amount of acidic lipid spotted per lane was equivalent to 200 
µg of tissue dry weight. The bands were visualized by charring with 3 % cupric 
acetate in 8 % phosphoric acid solution. BMP content did not increase in 
Sandhoff Disease mice brain with LPS induced brain inflammation. Std Standard 
is a mixture of purified acidic lipids including BMP 
Bis(monoacylglycero)phosphate; CL cardiolipin; PA phosphatidic acid; Sulf 
sulfatides; PS phosphatidylserine  and PI phosphatidylinositol. 	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Figure 8. Mass Spectrometry analysis of BMP in Sandhoff disease mouse 
brain. Triple-stage quadrupole (QqQ) mass spectrometer of (A) C18:1, 18:1 
commercial BMP standard, (B) C18:1, C16:0 commercial PG standard and (C) BMP 
obtained from Sandhoff Disease mouse brain. 
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Table 1. BMP levels in the brains of mouse, cat, bear, and human with 
ganglioside storage disease 
Species  Age Phenotype  Tissue n    BMP a Fold increase 
Mouse Adult Normal Brain 6 42.7 ± 11.5   
 Adult SD Brain 3 148.6 ± 22.6 
c 3.4 
 Adult GM1 Brain 3 256.0 ± 11.9 
c 6.0 
 Juvenile 
b Normal Brain 3 17.9 ± 2.0  
 Juvenile 
b SD Brain 2 109.0 ± 9.4 c 6.0 
 Adult Normal Liver 3 ND  
  Adult SD Liver 3 243.9 ± 171.0 >50 
Cat Adult Normal Brain 3 12.0 ± 17.3   
 Adult SD Brain 3 219.6 ± 16.0 
c 18.3 
  Adult GM1 Brain 2 370.4 ± 61.1 c 30.8 
Bear Adult Normal Brain 1 12.2   
  Adult GM1 Brain 1 184.2  15.0 
Human Adult Normal Brain 1 29.5   
  Adult SD Brain 1 451.1  15.3 
a  BMP levels are represented as µg/ 100 mg of tissue dry weight. ND=Not Detected   
b Juvenile mouse brains are analyzed at P15  
c Significantly different than normal sample in the same group using student t-test (p<0.05). 
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Table 2. Fatty acid distribution of brain BMP from mouse, cat, bear, and 
human with ganglioside storage disease 
                
Species    Mouse     Cat  Bear  Human 
Phenotype SD GM1    SD  GM1 GM1    SD 
n  3   3   3   2  1  1 
Fatty acids                
C16:0 9.0 ± 1.8 5.4 ± 0.5 5.4 ± 1.1 10.9 ± 0.6 3.5  4.3 
C18:0 10.4 ± 1.8 8.7 ± 0.8 15.4 ± 2.7 24 ± 0.9 5.4  33.0 
C18:1 11.5 ± 1.9 11.7 ± 0.6 21.7 ± 3.3 22.6 ± 0.9 10.7  24.2 
C18:2n-6 1.5 ± 0.4 1.2 ± 0.1 5.2 ± 0.4 2.0 ± 0.5 3.0  4.9 
C20:2 2.0 ± 0.6 2.6 ± 1.2 0.5 ± 0.4 1.6 ± 0 0.6  4.2 
C20:4n-6 7.2 ± 0.4 8.0 ± 0.4 6.6 ± 0.7 5.9 ± 0.2 13.8  5.9 
C20:5n-3 ND 4.4 ± 1.7 8.5 ± 3.0 0.4 ± 0.2 0.3  ND 
C22:6n-3 58.4 ± 4.8 57.9 ± 2.4 36.7 ± 2.9 32.7 ± 1.4 62.6  17.2 
C24:0 ND ND ND ND 9.6  6.3 
                                
Mouse and cat brain samples are obtained from GM1 and GM2 gangliosidosis(SD) effected 
animals as described in materials and methods. Bear and human samples are obtained from 
post-mortem diseased subjects.Values represent mean percentage distribution of fatty acid ± 
interquartile range of independent samples where n≥2. ND=Not Detected 
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Table 3. Influence of AAV gene therapy on the content of GM2 and BMP in 
Sandhoff Disease mouse brain 
 
Sample Phenotype Treatment GM2 a BMP b 
1 normal none ND 66.8 
2 normal none ND 72.1 
3 normal none ND 61.9 
4 SD none 357.7 180.0 
5 SD none 376.7 162.5 
6 SD none 347.8 179.3 
7 SD none 391.1 187.5 
8 SD AAV 4.4 74.3 
9 SD AAV 16.4 74.5 
10 SD AAV 34.9 81.8 
11 SD AAV 23.0 81.4 
12 SD AAV 39.1 85.2 
13 SD AAV 4.1 70.2 
a GM2 values are expressed as µg sialic acid/100 mg of tissue dry weight. ND=Not Detected 
b BMP values are expressed as µg /100 mg of tissue dry weight  
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Discussion  
	  
Although BMP comprises a small portion of total phospholipids in normal tissues, 
BMP levels increase in many LSDs such as Niemann-Pick, neuronal ceroid 
lipofuscinoses, mucopolysaccharidosis (MPS I and II), Fabry disease, and 
Gaucher disease [27, 28, 30-34, 66, 67].  However, no detailed studies of BMP 
content and composition have been conducted in the brains of ganglioside 
storage diseases [37].   We observed a dramatic increase of BMP levels in GM1 
and GM2 gangliosidoses brain samples in humans, American black bear, cats, 
and mice compared to their non-diseased counterparts. LSDs frequently involve 
a secondary storage material in addition to the primary storage material [37, 68]. 
Examples include secondary ganglioside storage in Gaucher disease, and MPS, 
and secondary cholesterol storage in Niemann Pick disease [69].   
 
We found that BMP was stored as a secondary material in the brains of GM1 and 
GM2 gangliosidoses. An explanation for the secondary storage of BMP in 
gangliosidosis brain has not been established [38]. Since BMP is localized to 
endosomal/lysosomal membranes [70], a lysosomal expansion from stored 
gangliosides could simply increase the amount of a lipid localized in these 
compartments. However, BMP does not increase proportionally with lysosomal 
size, and it is not stored as a secondary material in all LSDs [38].  Hence, 
lysosomal expansion might not be the only mechanism for BMP elevation [31, 
38].  
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It is also unlikely that BMP storage is linked directly to the primary enzyme 
deficiency in LSDs, as BMP storage was not observed in the liver of GM1 
gangliosidosis (β-gal(-/-)) mice despite the presence of ganglioside storage in the 
brain of these mice (data not shown).   GM1 is not stored in the liver of β-gal (-/-) 
mice, as GM1 synthesis does not occur in mouse liver [71]. On the other hand, 
BMP storage was observed in the liver of Sandhoff Disease mice (Table 3), 
where GM2 and GA2 are also stored [71]. This observation indicates that BMP 
co-accumulates with ganglioside storage, rather than as a downstream by-
product of a non-functional enzyme. We also observed an enrichment of BMP in 
brain microsomal fractions that were obtained from β-gal -/- mice. This 
observation is consistent with our previous finding of GM1 enrichment in this 
fraction [61]. These findings support further the co-localization of BMP with the 
abnormal ganglioside accumulation. Since we did not perform a detailed analysis 
of BMP accumulation in the microsomal fraction, BMP might co-localize with 
GM1 in endo-lysosomes, microsomes or mitochondria-associated ER 
membranes [72]. Further studies needed to resolve this issue. 
 
Kobayashi et al showed that BMP plays a role in the formation, structure, and 
trafficking of endosomal/lysosomal compartments in cells under normal 
conditions [2, 70, 73]. Late endosomes/lysosomes form multivesicular bodies 
under normal conditions, but form multilamellar vesicles in pathological cases 
such as the gangliosidoses [74, 75].  Both gangliosides and BMP are thought 
necessary for the formation of these aberrant lamellar bodies. It is possible that 
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the high BMP levels we observed in the brains from the GM1 and GM2 
gangliosidoses contribute to the formation of these multilamellar storage vesicles.  
 
Glycosphingolipids are degraded in lysosomes with the aid of hydrolases and 
lysosomal lipid binding proteins, e.g. saposins [19, 76]. The lipid composition of 
lysosomes is thought to be important in this degradation, and anionic 
phospholipids such as BMP are thought to facilitate the degradation of 
glycosphingolipids in the limiting membrane of endosomal/lysosomal 
compartments [77]. BMP facilitates cholesterol transport, and the application of 
anti-BMP antibodies leads to cholesterol accumulation in lysosomes, mimicking 
the Niemann Pick phenotype [78].  BMP becomes limiting in Niemann pick 
disease fibroblasts, and exogenous feeding of BMP decreases excessive 
cholesterol storage [18]. Also Hein et al show that selective decrease of BMP, 
reduces the storage material glucosylceramide in THP-1 Gaucher macrophages 
[26] Further studies will be needed to determine if modulation of BMP levels can 
decrease ganglioside storage in the GM1 and GM2 gangliosidoses. 
  
Inflammation is a hallmark of the gangliosidoses [79]. Microglial infiltration is 
observed with the onset of behavioral symptoms (about 2.5 months) in Sandhoff 
Disease (Hexβ (-/-)) mice and GM1 gangliosidosis (β-gal -/-) mice [79, 80].  Since 
BMP is a major lipid in alveolar macrophages, it is possible that 
microglial/macrophage infiltration could contribute in part to the increased BMP 
levels observed in the brains of the gangliosidoses.  To address this possibility, 
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we analyzed BMP levels in young Hexβ (-/-) mice at postnatal day 15 (p15), well 
before the onset of behavioral symptoms and inflammation.  However, GM2 
gangliosides storage is observable in the p15 Hexβ (-/-) mice [71].  We found that 
brain levels of BMP were higher in the p15 Hexβ (-/-) mice than in the normal age 
matched controls. Also In order to test a possible disease associated-microglia 
infiltration contribution to BMP levels, we induced microglia proliferation with i.p 
injections of LPS.  However, BMP levels were similar in Sandhoff Disease mouse 
brain injected with LPS or saline (PBS). These findings suggest that BMP 
storage is not likely associated with inflammation, but is associated with 
ganglioside storage. 
 
Adeno-associated viral (AAV) gene therapy has been successfully used to treat 
GM1 and GM2 gangliosidosis in both mice and cats [63, 64, 81-83]. Vectors 
expressing the deficient enzymes needed for corresponding ganglioside 
degradation are delivered intracranially. AAV treatments can successfully restore 
the deficient enzymatic activity and eliminate most of the corresponding 
ganglioside storage [63, 64, 81-83]. We observed that AAV treatment also 
eliminated secondary storage of BMP in Sandhoff Disease mouse brains. A 
significant positive correlation was observed between BMP storage and GM2 
storage in the AAV-treated and untreated mice. These results show that AAV 
therapy that targets the primary storage successfully clears the secondary BMP 
storage as well.  
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Another property of BMP is its unique fatty acid composition. C18:1 is a major 
BMP fatty acid in many cell types [11-13, 15, 84, 85].  In alveolar macrophages, 
BMP predominantly contains n-6 fatty acids such as linoleic acid (18:2) and 
arachidonic acid (20:4) [10, 86]. Interestingly, docosahexaenoic acid (DHA, 
C22:6, n-3) comprises a significant portion of BMP fatty acids in many cell types, 
in drug-induced phospholipidosis, and also in many LSDs [12, 13, 15, 33, 84, 87-
92].  We also found that DHA was a major fatty acid species in BMP from the 
brains of mouse, cat, and bear with gangliosidosis.  This predominance was most 
dramatic in mouse and bear samples where DHA comprised 57-62% of the BMP 
fatty acids. The reason for this high DHA percentage is unclear. Polyunsaturated 
fatty acids can influence membrane fluidity, which might be important for control 
of endosomal sorting and membrane fusion. Bouvier et al showed that 22:6/22:6 
BMP can be oxidized in the presence of oxygen radicals [15], thus protecting 
cholesterol from oxidation.  However, the specific function of 22:6 in LSDs 
remains unclear [38].  
 
Here we analyzed the content and fatty acid composition of BMP in humans and 
in animals (mice, cats, American black bears) with either GM1 or GM2 
ganglioside storage disease.  Our results showed that BMP was a significant 
secondary storage material in the gangliosidoses.  BMP storage might be linked 
to lysosomal size, or might have a functional role in clearing excess storage 
material.  Further studies will be needed to address these issues. 
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CHAPTER 2 	  
Introduction 
 
Macrophages are the major phagocytes of the immune system, digesting intra-
cellular material by autophagy, or extracellular material engulfed by endocytosis. 
Engulfed materials are either recycled to the plasma membrane or are directed to 
the lysosomes by endosomal transport. Early endosomes mature into late 
endosomes and then lysosomes, while forming intraluminal vesicles for efficient 
sorting and degradation of the cargo [93]. BMP is enriched in intraluminal 
vesicles, representing up to 70% of the phospholipids [73].  While the diameter of 
lysosomes is around 1.0 micron in most cell types, the diameter in macrophages 
can reach up to several microns [94]. 
In most mammalian cells, BMP levels are low, comprising only about 1-2 % of 
total phospholipids. However, BMP constitutes 16% of the total phospholipids in 
lung alveolar macrophages [10]. In this work, we show that BMP comprises a 
significant portion of phospholipids in various mouse cells of macrophage origin 
compared to cell lines of macroglial origin, such as oligodendrocyte progenitors 
and astrocytes. BMP, with its unique properties in lysosomal function and 
storage, could be an important lipid for macrophage biology and function. 
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Materials and Methods 
 
Origin of the VM-M3, VM-M2 and CT-2A tumor cells 
	  
Spontaneous VM-M3 and VM-M2 tumors were identified in the cerebrum of 
VM/Dk inbred mice that showed cranial swelling and lethargy during routine 
examination. Tumors were passaged in brain and maintained in vivo as 
previously described [95].  The CT-2A was produced with intracranial chemical 
carcinogen implantation into C57BL/6J mouse brain as previously described [96].  
CT2A is an NG2-rich stem cell-like murine glioma [97-99] 	  
Cell lines and culture conditions 
	  
VM-M3, VM-M2 and CT-2A clonal cell lines were generated from the primary 
tumors by tissue disassociation and cell culture seeding. The macrophage RAW 
264.7, BV2 and the mouse astrocyte C8-D30 (Astrocyte type III clone) cell lines 
were purchased from American Type Culture Collection (Manassas, VA). The 
cell lines were grown in high glucose (25 mM) Dulbecco’s modified Eagle 
medium (DMEM, Sigma, St. Louis, MO) supplemented with 10% fetal bovine 
serum (FBS, Sigma) and 50 lg/ml penicillin– streptomycin (Sigma).  The cells 
were maintained in 95% air and 5%CO2 at 37oC in a CO2 incubator. 
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Peritoneal macrophage isolation 
	  
Peritoneal macrophages were isolated as previously described [100]. Briefly, 
adult VM mice (3-4 months old) received 1.0 ml intraperitoneal injection of 
Brewer’s thioglycollate broth.  The mice were euthanized with CO2 four days 
after the injection, and the peritoneal area was cleaned with 70% ethanol. Ice-
cold PBS (10 ml) was injected intraperitoneally and cells were collected with an 
18-gauge needle, and immediately transferred to a 50 ml conical tube on ice. 
Elutes that had blood contamination were discarded. Cells were spun at 400 x g 
for 10 min and re-suspended in high glucose (25 mM) Dulbecco’s modified Eagle 
medium supplemented with 10% fetal bovine serum and 50 Ulg/ml penicillin– 
streptomycin.  Cells were washed with PBS 3-4 hours after initial seeding and 
were cultured in DMEM for 24 hours before collection. 
Lipid isolation, purification, and quantification 
See Chapter 1 Materials & Methods for details. 
Gas chromatography 
See Chapter 1 Materials & Methods for details. 
Statistical analysis 
See Chapter 1 Materials & Methods for details. 
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Results 	  	  
BMP levels in cells with macroglial and microglial/macrophage origin 	  	  
Our goal was to determine if the amount of BMP differed between normal cells 
and tumor cells classified as microglia/macrophages (VM-M3, VM-M2, BV2, and 
peritoneal macrophages), and the cells classified as macroglia (murine 
astrocytes and CT-2A).  BMP levels were significantly greater in cells of 
microglial/macrophage origin than in cells of macroglial origin (Figure 9, Table 4).   
BMP represented only about 1.8 - 3.7% of total phospholipids in the CT-2A tumor 
cells and astrocytes, whereas it represented 7.1 - 10.4% in the 
microglia/macrophage cells. 
 
Fatty acid distribution of BMP from cells with macrophage/microglia origin 
 
C18:1 was the predominant fatty acid species in BMP obtained from the cultured 
macrophage/microglia cell lines (VM-M3, VM-M3, RAW and BV2), comprising 
49.8 - 66.9% of the total fatty acids (Table 5). BMP from these cell lines also 
expressed C16:0, C16:1, C18:0, C20:1, C20:4, C20:5 and C22:6 in variable 
percentages. However, C16:0 was the predominant fatty acid (21.5%), followed 
by C18:1 (19.7%), in thioglycollate-elicited peritoneal macrophages. The 
percentage of C22:6 was highest in BMP from thioglycollate-elicited peritoneal 
macrophages (18.0%) with a lower percentage in the cultured BV2 microglial 
cells (8.2%).	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Figure 9. HPTLC of acidic phospholipids from cell lines with macroglial 
(CT2A, astrocyte) and macrophage/microglial origin (VM-M3, VM-M2, RAW 
264.7, BV2, peritoneal macrophages (PM)). The amount of acidic lipid spotted 
per lane was equivalent to 300 µg of dry cell pellet weight. The bands were 
visualized by charring with 3 % cupric acetate in 8 % phosphoric acid solution. 
Std Standard is a mixture of purified acidic lipids including BMP 
Bis(monoacylglycero)phosphate; CL cardiolipin; PA phosphatidic acid; PG 
phosphatidylglycerol; PS phosphatidylserine  and PI phosphatidylinositol. 
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Table 4. BMP levels in cells with macroglial and macrophage/microglial origin 
	   	   	   	   	   	   	   	  
Cell Line Origin  BMP concentration a BMP % of total phospholipidsb 
CT2A Oligodendrocyte progenitor   47.9 ± 1.8             1.8 ± 0.1 
C8-D30  Astrocyte 122.8 ± 7.8             3.7 ± 0.1 
VM-M3 Macrophage/ Microglia 202.3 ± 3.9
c             7.2 ± 0.2 
VM-M2 Macrophage/ Microglia 215.5 ± 4.0
c             7.1 ± 0.2 
RAW Macrophage 294.3 ± 7.5c           10.4 ± 0.1 
BV2 Microglia 214.0 ± 5.3c             7.1 ± 0.1 
PMd Macrophage 226.6 ± 15.9c            8.1 ± 0.5 
        a  BMP levels are represented as µg/ 100 mg of cell pellet dry weight    b BMP % phospholipid values are calculated by amount of BMP divided by amount of total phospholipids 
c Significantly different than non-macrophage lineage cell lines (CT2A and astrocyte) (p<0.01). 
d Peritoneal Macrophages. 
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Table 5.  Fatty acid distribution of BMP from cells with macrophage/microglia origin 	  
                
           VM-M3         VM-M2      RAW 264.7                 BV2              PM 
Fatty acids                
C16:0 15.4 ± 4.6 12.6 ± 5.6 3.6 ± 0.8 4.2 ± 2 21.5 ± 4.8 
C16:1 5.9 ± 0.3 9.7 ± 0.7 4.8 ± 0.2 1.9 ± 1 2.6 ± 0.8 
C18:0 3.5 ± 1.6 6.1 ± 0.1 2.9 ± 0 12.3 ± 0.9 9.8 ± 1.7 
C18:1 49.8 ± 11.4 66.9 ± 4 65.6 ± 1.8 65 ± 0.6 19.7 ± 4.2 
C18:2n-6     ND  3.8 ± 2.2  ND  5.5 ± 0.6 
C20:0  ND   ND  2.5 ± 0.1 1.7 ± 0.4  ND  
C20:1  ND   ND  6.6 ± 0.2  ND  1.7 ± 1.4 
C20:2 9.9 ± 3.3  ND  2.6 ± 0.2  ND   ND  
C20:3 5.2 ± 2.5  ND   ND   ND   ND  
C20:4n-6 11.3 ± 4.9  ND  1.3 ± 0.2  ND  3.2 ± 0.7 
C20:5n-3 2 ± 0.7  ND  2.6 ± 0.4 6.7 ± 1.6 14.8 ± 2.7 
C22:6n-3 0.8 ± 0.1 1.7 ± 1.1 2.5 ± 0.2 8.2 ± 2.3 18.0 ± 2.6 
C24:0  ND   ND  0.5 ± 0  ND   ND  
C24:1  ND   ND   ND   ND  3.8 ± 1.2 
 
Values represent mean percentage distribution of fatty acid ± standard deviation of 3 samples, except peritoneal 
macrophages (PM) where n=6.  
ND= Not Detected 
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Discussion 	  
BMP represents 1-2% of all the phospholipids in many cell types, except in 
alveolar macrophages, where it represents 16% of phospholipids [10]. Here, we 
confirmed that cells with macrophage/microglia origin had significantly higher 
BMP content compared to non-macrophage cell lines. BMP enrichment in 
macrophages could be linked to the increased size of their endo-lysosomal 
capacity [94]. In this study, we evaluated BMP content in both tumorigenic (VM-
M3, VM-M3, CT2A, RAW) and non-tumorigenic (BV2, Peritoneal macrophages, 
astrocytes) cell types. BMP levels were not correlated with the tumor forming 
capacity of these cells, making it unlikely that BMP levels are linked with 
tumorigenic potential. Recent work from Sandhoff and co-workers showed that 
BMP aids the degradation of glycosphingolipids by interacting with 
glycosphingolipid degradative enzymes and saposins in the lysosomes [14, 19, 
20]. Also, exogenous BMP decreased excess cholesterol storage in Nieman Pick 
fibroblasts [18, 101]. These observations suggest BMP might also have a 
functional role in macrophages. 
 
Pathological conditions involving macrophages might provide information 
regarding possible roles of BMP in macrophage biology.  The selective decrease 
of BMP can reduce glucosylceramide storage in Gaucher disease macrophages 
[26]. BMP might also have a role in macrophages associated with atherogenesis, 
and foam cell formation involving the cellular uptake of oxidized LDL (oxLDL) and 
enzymatically modified LDL (eLDL) particles.  Scavenger receptors and receptor-
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mediated endocytosis can internalize oxLDL particles. Increased BMP levels are 
associated with storage of partially degraded oxLDL particles in acidic 
compartments of macrophages. However, BMP levels are not increased in 
macrophages following uptake of eLDL particles that are stored in non-
endolysosomal lipid droplets and enriched in cholesterol and free fatty acids 
[102] .  Further studies are needed to determine if alterations in BMP content can 
influence oxLDL particle uptake by macrophages or oxLDL-mediated apoptosis.  
Vesicular Stomatitis Virus (VSV) and Human Immunodeficiency Virus (HIV) 
exploit the endosomal pathway for their release through the plasma membrane 
[103, 104].  Chapuy-Regaud recently showed that progesterone, the cationic 
amphiphile U18666A, and a phospholipase inhibitor (Methyl Arachidonyl Fluoro 
Phosphonate, MAFP) could increase BMP levels, and inhibit viral production in 
human monocytes and macrophages [104]. These observations suggest a critical 
role for BMP in macrophages, especially in certain diseases that involve the 
endo-lysosomal system. 
 
Although the highest levels of BMP were found in cells of macrophage/microglial 
origin, BMP comprised about 3.7% of total phospholipids in normal mouse 
astrocytes. This percentage was slightly higher than that found in the CT2A 
oligodendrocyte progenitor tumor stem cells (1.8%). Astrocytes release 
glutamate, D-serine, and ATP through Ca2+-dependent exocytosis [105]. While 
neurons use synaptic vesicles for neurotransmitter release, astrocytes use small 
vesicles and lysosomes, which are stained positively for endo-lysosomal markers 
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such as CD63/LAMP3, and VAMP7, for gliotransmitter release [106]. The slight 
elevations of BMP observed in astrocytes might be linked to these endo-
lysosomal associated vesicular compartments. This observation suggests that 
BMP might be enriched in other cell types that use the endo-lysosomal system 
for their specific cellular functions, but additional studies are needed to support 
this hypothesis.  
 
We observed fatty acid heterogeneity in BMP isolated from different macrophage 
cell types.  The levels of C:18-1 were higher in the cultured 
macrophage/microglia cell lines (49-66%) than in the peritoneal macrophages 
(19%).  In contrast, the distribution of C16:0 and polyunsaturated fatty acids 
(C20:5n-3 and the C22:6n-3) were significantly higher in the peritoneal 
macrophages than in the cultured macrophage/microglia cell lines. As discussed 
in Chapter I, C22:6 was present in BMP in high percentages from gangliosidosis 
brain. These findings suggest that the culture environment might cause 
differences in the BMP fatty acid profile of macrophages and cells might 
synthesize longer and more diverse fatty acids in their natural in vivo 
environment. We previously showed that the cell culture environment inhibited 
fatty acid remodeling of cardiolipin in normal mouse astrocytes leading to 
elevated levels of saturated and monounsaturated fatty acids and reduced levels 
of polyunsaturated fatty acids [107].  We suggested that this phenomenon 
resulted from the suppression of oxidative phosphorylation through the Crabtree 
effect, as high lactate levels indicative of fermentation metabolism were seen in 
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the cultured astrocytes.  Further studies will be needed to determine if the BMP 
fatty acid differences observed between the macrophages grown in vitro and 
those grown in vivo result from differences in growth environment. 
 
BMP enrichment in macrophages could be due simply to the increased 
lysosomal size observed in this type of cell.  However, BMP has functional roles 
in endosomes and lysosomes such as controlling endosomal sorting and aiding 
the degradation of glycosphingolipids [19, 20, 70, 78, 101].  BMP might also have 
a critical role in macrophages under certain pathological conditions described 
above. Hence modulating BMP levels in macrophages might provide therapeutic 
insights in diseases involving the endo-lysosomal system such as atherogenesis, 
lipid storage diseases, and viral infections. 
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CHAPTER 3 
Introduction 
Glioblastoma Multiforme (GBM) 	  
GBM is the most common brain cancer type in adults [108]. It has the worst 
prognosis among brain cancers, and the survival period is generally less than 12 
months [109]. GBM has an invasive nature, spreading to many regions of the 
brain (with sub-pial, sub-ventricular, perivascular, perineuronal, intra-fesicular 
invasion) forming the “Secondary Structures of Scherer”	  [110]. It also invades the 
contralateral hemisphere. Therefore, it is almost impossible to surgically remove 
all tumor tissue in GBM patients, which is also another cause of the poor 
prognosis GBM is not considered a metastatic tumor due to low frequency of 
distant tissue or organ metastasis	   [111]. However, recent research shows that, if 
it reaches extraneural sites, it can metastasize to other tissues [112-115]. From 
our perspective, a highly invasive cancer type is expected to be metastatic, since 
these phenomena are generally linked to each other [116, 117]. GBM is most 
commonly considered to have an astrocyte-like origin. However, it has a widely 
mixed population of cells with different morphology, and expresses different cell 
origin markers seen in astrocytes, neurons and mesenchymal cells [118-121] We 
hypothesize that neoplastic macrophage/microglia present in GBM and 
contributes to highly invasive nature of GBM[122] .  
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VM mouse as a GBM and metastatic tumor model 
 
The VM mouse strain has a high rate (1.5%) of spontaneous brain tumor 
development. Three brain tumors from these mice have been obtained in our 
laboratory [95, 123]. Two of them (VM-M2 and VM-M3) are highly invasive when 
injected orthotropic to brain, and are highly metastatic to distant organs such as 
lung, liver and spleen when injected to non-brain regions as flank (Figure 10) 
[95]. These two metastatic tumors have macrophage-like characteristics defined 
by morphology and gene expression [95]. The other tumor, VM-NM1 has a 
neural stem cell like origin and was not invasive in the brain or metastatic when 
implanted in flank [95]. VM-M3 tumor also manifests all the infiltrative patterns of 
“Structures of Scherer” seen in Glioblastoma Multiforme when injected intra-
cranially [124]. These phenomena are not observed in most of the GBM models, 
except in the chemically induced CNS-1 rat glioma model [125, 126]. Numerous 
in vivo mouse tumor models require an inducement of a chemical for the tumor 
formation, which is not the case for most spontaneously occurring human tumors 
[127].  
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Figure 10. VM-M3/fluc metastatic tumor model (A) Dorsal and ventral images 
VM-M3/fluc subcutaneous tumor bearing VM mouse  (B) Representative images 
of liver and lung metastasis  (C) Ex vivo quantification of distant organ metastasis 
by photon count	  [95]. 
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Xenograft mouse models, in which the human tumors are injected into immune 
compromised mouse models, are often used for in vivo tumor analyses [128]. 
Unfortunately, due to the absence of mouse immune system, tumor cells do not 
experience the natural tumor environment factors such as inflammation, which 
also contributes to the growth and metastasis of the tumor cells [129] [130]. 
Xenograft grown human tumor cells uptake murine carbohydrates and lipids, 
causing the generation of mouse-human hybrid cells [131]. Also basal metabolic 
rate of a mouse cell is 8-10 times higher than human cells [132].  Considering all 
these artifacts, it is very unlikely that Xenograft tumor models can recapitulate the 
natural tumor growth behavior and assess the effect of potential therapies [133] 
[134]. Most naturally invasive tumors (such as GBM) do not invade when grown 
as Xenografts [127]. In order to observe a distant site metastasis, tumor cells are 
generally injected intravenously, which already bypasses the first steps of 
metastasis [133, 135]. VM-M3 cells show all characteristics of metastatic tumor 
cells including local invasion, intravasation, immune system survival and 
extravasation [95, 136]. The inability to study cancer in its natural environment, or 
in its original background is one of the rate limiting steps in cancer biology [136]. 
These issues illustrate the importance of the VM-mouse model system for 
studying the metastatic behavior of tumor cells.  
 
Abnormal metabolism of tumors 
 
Cancer cells alter their metabolism through a high glycolytic phenotype rather 
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than oxidative phosphorylation [137]. In normal cells, under aerobic conditions, 
pyruvate generated from glucose enters to mitochondria and generates NADPH 
in TCA cycle, which is then used for ATP generation through electron transport 
chain in mitochondria [138]. However, under anaerobic conditions, such as 
oxygen limitation resulting from excessive exercise, pyruvate is fermented to 
lactate in the cytosol instead of entering into mitochondria [138]. Otto Warburg 
discovered that cancer cells generate most of their ATP through glucose 
fermentation in the presence of oxygen [139]. This discovery was later named as 
“Warburg Effect”. Otto Warburg stated that insufficient respiration causes cancer 
initiation, and glycolysis compensates for the insufficient respiration [140, 141]. 
After this discovery, many findings suggested that there were mitochondrial 
abnormalities in cancer cells [142-147]. Cardiolipin (CL) is a phospholipid found 
in the inner mitochondrial membrane and it maintains coupled respiration and 
mitochondrial functionality. Kiebish et al found that CL content was lower, and CL 
molecular species were altered in tumor tissues, suggesting major defects in CL 
synthesis and remodeling.  The tumor tissues also had lower electron transport 
chain activities compared to normal tissues. As Pederson states, tumor 
mitochondria are markedly different in morphology, lipid and protein profile 
compared to normal mitochondria [148]. Tumor mitochondria also have many 
defects in electron transport chain, calcium shuttle and anion membrane 
transport; thus pyruvate cannot be properly oxidized for ATP generation [148]. 
Therefore, cancer cells need to compensate their insufficient respiration through 
upregulation of fermentation for ATP generation [134, 141]. Most tumor cells do 
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not obtain enough oxygen in necrotic and poorly vascularized tumor core. This 
hypoxic environment causes Hypoxia Induced Factor 1 (HIF1) upregulation, 
which causes an upregulation in glycolytic pathways [149]. HIF1a also can be 
upregulated due to defective mitochondria, which further links this hypoxia-
initiated glycolytic phenotype to mitochondrial abnormalities [150]. Therefore, 
high uptake of glucose and upregulation of glycolytic pathways are obligatory in 
cancer cells with respiratory defects [141, 151]. 
 
Reactive oxygen species (ROS) can form from electron leakage during oxidation 
reactions in mitochondria [152]. These reactive oxygen molecules can attack 
proteins, DNA, and lipids, eventually leading to cell death [153]. They can cause 
membrane damage because of lipid peroxidation of polyunsaturated fatty acids, 
which results in changes in the membrane fluidity, permeability, and inactivation 
of membrane proteins [154]. There is a substantial amount of research indicating 
a significant increase in intracellular O2 and H2O2 in cancer cells relative to 
normal cells [155]. Cardiolipin deficiencies and higher proton leak observed in 
tumor mitochondria might explain the reason for high ROS levels in tumor cells 
[148]. High glycolysis, and glycolytic regulators such as PKM2, causes a flux 
through the pentose phosphate pathway (PPP), and upregulate antioxidant 
systems through NADPH generation. NADPH generated through PPP also 
supplies the high macromolecule demand of cancer cells [156].  Therefore, 
cancer cells are highly dependent on glucose utilization for anti-oxidant 
mechanisms in order to cope with their high ROS levels [157]. 
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Calorie restriction 
 
Glucose dependency of cancer cells has been exploited by tumor detection with 
(18F) fluorodeoxyglucose positron emission tomography (FDG–PET) imaging 
[158].  However, cancer therapies exploiting cancer abnormal metabolism are 
very limited and not widely used in standard practice [151]. If all cancer cells 
suffer from respiratory insufficiency, treatments that target glycolysis should be 
very effective in managing cancer [134]. Inhibition of glycolysis can be obtained 
by drugs that target glycolytic pathways, such as dichloroacetate, 2-
deoxyglucose and 3-Bromopyruvate [159-163]. However, restriction of calorie 
intake is a more natural way of targeting glycolysis, which decreases blood 
glucose levels in natural ways [164]. Calorie restriction (CR) has been shown to 
reduce growth of many human and mouse tumors types [165-168]. CR reduces 
the growth of tumor cells in many ways such as restricting the availability of 
glucose as a fuel to cancer cells, targeting nutrient sensing and growth signaling 
pathways such as PI3K/Akt/HIF1α/IGF1, and controlling tumor environment that 
contribute to tumor pathogenesis by reducing angiogenesis and inflammation 
[168-172]. Glucose withdrawal and the conversion to lipid metabolism increases 
oxidative stress, leading to apoptosis in cancer cells [173]. Restriction of glucose 
can also selectively target cancer cells that rely on glucose for ROS detoxification 
[174]. 
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Ketogenic diet  
 
Glucose deficiency in the blood causes the liver to oxidize fatty acids into ketone 
bodies (KB), which later on get exported to other tissues, where they are used as 
an energy source [175]. In order to drive cellular respiration, these ketones, the 
majority of which are acetoacetate and β-hydroxybutyrate, are then converted 
into acetyl-CoA [176]. Ketones can be elevated in blood by either fasting, with 
long-term calorie restriction or by high fat (ketogenic) diets [177-179]. With these 
methods, due to a limited carbohydrate intake, body’s stored glycogen is 
depleted and there is a transition to the fat dependency for energy, which is 
termed as the state of ketosis [179]. Ketogenic diets, with high fat: protein + 
carbohydrate ratios are alternative ways to reduce blood glucose levels and 
increase high ketone levels, and these diets are safely used as treatments in 
some pathological conditions such as epilepsy [180, 181]. Ketogenic diets might 
be an alternative way to reach the therapeutic effects of calorie restriction, which 
can also provide additional therapeutic benefits. Ketones are directly converted 
to acetyl-CoA, therefore they can be used for ATP generation only in 
mitochondria for oxidative phosphorylation in normal cells [182]. Considering 
mitochondrial defects and apparent respiratory insufficiency, ketones might not 
be metabolized in cancer cells efficiently. Therefore ketogenic diets can be a very 
useful treatment strategy, to selectively kill tumor cells [182, 183]. Ketogenic diets 
are shown to be effective in reducing the tumor growth in animal models of 
glioma, non-small lung cancer, colon cancer, gastric cancer and prostate cancer 
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in animal tumor models [163, 184-187]. Ketogenic diets have also been shown to 
increase the therapeutic effects of conventional cancer therapies, such as 
chemotherapy and radiation [188, 189]. 
 
Ketogenic diets may have additional therapeutic benefits due to their correlation 
with reactive oxygen species (ROS) production in cells. In normal cells, β-
hydroxybutyrate metabolism increases reduction of NAD+ and increases 
oxidation of coenzyme-Q; thus resulting in lower semiquinone levels, which 
decreases superoxide production [190]. Through this mechanism, ketones could 
lower ROS in normal cells and therefore protect cells from oxidative damage 
[190]. However, ketones force cells to use oxidative phosphorylation and this 
might result in increased O2 leak from the mitochondria in cancer cells due to 
their defective mitochondria. Ketones are shown to increase reactive oxygen 
species in cancer cells, yet contrary results are also presented in literature [191, 
192]. Recently Poff et al. showed that, a combination of ketogenic diet and 
hyperbaric oxygen therapy resulted in a decreased tumor growth rate and 
increased mean survival time in VM-M3 tumor model system [191]. These 
findings suggest that ketones might further increase the ROS levels in cancer 
cells beyond the levels that they can not cope with in the absence of glucose. 
Therefore ketogenic diets, which lower the blood glucose and increase ketones, 
can be an alternative and non-toxic therapy for the management of tumor growth, 
invasion and metastasis [134]. 
In this chapter of my thesis, I examined the effects of different diets on VM-M3 
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tumor growth and metastasis. I observed that restricted KetoGen ketogenic diet 
(KG-R) reduced VM-M3 tumor growth and distant organ metastasis, and 
increased the survival of VM-M3 tumor bearing mice significantly. KG-R was able 
to reduce blood glucose and increase β-hydroxybutyrate levels significantly 
compared to control (SD-UR) groups. These results suggest that restricted 
KetoGen ketogenic diet might be an alternative non-toxic therapy for managing 
metastatic cancers. 
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Materials and Methods 
Mice 	  
VM/Dk (VM) strain mice were obtained as gifts from H. Fraser (University of 
Edinburgh, Scotland) and from G. Carlson (McLaughlin Research Institute, Great 
Falls, Montana). Housing and breeding of all mice used for this study were done 
in the Boston College Animal Care Facility, utilizing husbandry condition as 
described elsewhere [193]. All animal procedures used for this study were 
approved by the Institutional Animal Care Committee and were in strict 
accordance with the National Institute of Health Guide for the Care and Use of 
Laboratory Animals. 
Origin of VM tumors 	  
As previously described	  [95], VM-M3 tumor arose spontaneously in the cerebrum 
of adult VM mice. With a routine examination of the VM mouse colony over 
several years, the VM-M3 tumor was detected (between 1993-2000). The tumors 
in the cerebrum were poorly defined masses with volumes about 3 x 1 x 1 mm, 
which are similar to previous spontaneous tumor descriptions in the VM mouse 
brain	   [123, 194]. Preservation of in vivo viability was established by immediately 
resecting and implanting each tumor intracerebrally (i.c.) into the host VM mice. 
This procedure is described below in detail. Tumors were passaged into several 
host VM vice right after cranial dome appearance. Three i.c. passages were 
required before the tumors were grown subcutaneously and cell lines were 
prepared from each tumor. Environmental variability was reduced by culturing all 
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cell lines under identical conditions. 
Intracranial implants 	  
Tumor implantation was performed as previously described [193]. Briefly, mice 
were anaesthetized with Avertin (0.1mL/10g). Ethanol was used to disinfect the 
top of the heads, followed by a small incision made in the mouse’s scalp over the 
midline. A 3mm3 burr hole was made in the skull lateral to the sagital suture and 
over the right parietal region behind the coronal suture.  
A small (about 1mm3) tumor fragment was implanted into the burr hole in the 
skull by using a trocar. Colloidon was used to immediately closing the flaps of 
skin. All mice reached morbidity at around 12 to 15 days period. All methods 
resulted in the 1.5 to 2 mm deep implantation of tumor fragments into the cortical 
region as described elsewhere [195]. Mice were housed in a warm room of 37°C 
temperature until they recovered fully. 
Subcutaneous implants 
VM mice were anaesthetized with Isoflurane (obtained from Halocarbon, River 
Edge, NJ) for s.c. implantation, and the tumor implantation was carried by a s.c. 
injection of 0.1 ml of tumor pieces suspended in 0.2 ml PBS, by the utilization of 
a 1 cc tuberculin syringe attached to an 18- gauges needle into the right flank. 
After all mice recovered from the surgical procedure, they were returned to their 
cages once they became fully active.  
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Bioluminescent imaging 	  
Bioluminescent signal from the luciferase labeled tumors were recorded with the 
Xenogen IVIS system (obtained from Xenogen, Hopkington, MA), as described 
elsewhere	   [95]. An intraperitoneal injection of D-Luciferin (50mg/kg, Xenogen) 
and Avertin (0.1 mL/10g) were given to mice for in vivo imaging. Depending 
based on the time point, imaging times changed from 30 seconds to 15 minutes. 
Organs were removed entirely and rinsed in PBS for ex vivo imaging. Organ 
imaging was performed in 300 µg/ml D-luciferin in PBS for 2 minutes after 2 
minutes of incubation. Brains were removed and split down through the midline 
for i.c. studies. Each hemisphere imaging was performed separately in 300 µg/ml 
D-luciferin in PBS for 2 minutes. Imaging of the right and left hemispheres was 
performed separately. 
Diets 	  
Standard high carbohydrate mouse chow diet (SD) is a nutritionally complete diet 
and was purchased from PROLAB chow (Agway Inc., NY). SD nutritional 
ingredients carbohydrate, fat, protein, and fiber comprised 62g, 6g, 27g of 100g 
of the total diet, respectively. KetoGen ketogenic diet (KG) and Vitamin and 
mineral mix (NanoVM 1-3 years) was a gift of Nancy Moore (Solace Nutrition, 
Pawcatuck, CT). KG is composed of 2.54g, 74g, 15.17g of carbohydrate, fat, 
protein for 100g of the total diet, respectively (information provided with personal 
communication). 9g of NanoVM added for 91g of KetoGen powder to make the 
complete formula. KetoCal®  ketogenic diet was purchased from Nutricia North 
	   66	  
America (Rockville, MD, formally SHS International, Inc.). KetoCal® is a 
nutritionally complete ketogenic formula and, according to the manufacturers 
specification, carbohydrate, fat, protein comprised 8.8g, 69.1g, 14.4 g of 100g the 
total diet, respectively. There are also minor differences between the two diets for 
the content (g/kg of diet) of amino acids, vitamins, minerals and trace elements. 
The KetoGen and KetoCal® diet was fed to the mice in paste form (water: 
KetoCal®; 1:2) within the cage. A comparison of the nutritional composition of the 
SD, KetoGen and the KetoCal® diet is presented in Table 7. 
Dietary feeding regimens, body weight, and food intake measurements 	  
Approximately 1 to 2 days before the tumor implantation, adult female and male 
VM mice (each mouse 60 to 120 days old) were separated into different 
housings. Each mouse was kept in plastic cages with Sani-Chip bedding (P.J. 
Murphy Products Corp., Montville, NJ) and with filter tops. SD food was provided 
ad libitum, food intake and body weight measurements were performed and 
recorded daily. Tumor fragment implantation took place on day zero. After 
confirming the presence of a tumor by imaging on the Xenogen Imaging System, 
mice were separated into groups matched for body weights 2-3 days after 
implantation. Mice were fasted 18 hours before diet (SD, KG, or KC) initiation. 
Mice on calorie restriction, received 40-60% of their food intake at around 10 AM 
(60% CR), in order to reach 18-20% body weight reduction compared to their 
initial weight, for the total duration of the study. Unrestricted (UR) mice received 
food ad libitum of their corresponding diet. Daily body weight measurements for 
	   67	  
all mice were performed prior to food administration. 
Measurement of plasma glucose, β-hydroxybutyrate and calculation of 
Glucose Ketone Index 
 
Blood collection from mice was performed on the last day of the study, before 
sacrifice and tumor resection. Before the blood collection, all mice were fasted for 
2 hours, in order to stabilize blood glucose levels. Mice were anesthetized with 
isoflourane (obtained from Halocarbon, NJ) and blood collected with 
submandibular bleeding in heparinized tubes. Collected blood was centrifuged at 
1,500 Å~ g for 10 minutes, after that the plasma was collected and stored at 
80°C until assayed. StanBio® Enzymatic Glucose Assay (1075-102) (obtained 
from StanBio Laboratory, Boerne, TX) and a modification of the Williamson et al., 
enzymatic procedure [196] was used to spectrophotometrically measure plasma 
glucose and β-hydroxybutyrate concentrations, respectively. For blood ketone 
body analysis, only β-hydroxybutyrate levels were measured since it is the major 
blood ketone body in plasma	   [175, 197]. Glucose Ketone Index is calculated by 
dividing mM glucose values to mM β-hydroxybutyrate levels	  [198].	  
 
Statistical analysis 
For calculating significance of organ metastasis with photons/sec values, non-
parametric Whitney Mann U Test was performed.  All other statistical analysis 
were performed using Student T-Test. 	  
 
	   68	  
 
Results 
Influence of diet on subcutaneous growth and distant organ metastasis of 
VM-M3/Fluc tumor 	  
In this experiment we analyzed whether feeding of VM mice with restricted 
standard diet, unrestricted ketogenic diet or restricted ketogenic diet has any 
effect on VM-M3 tumor growth and metastasis. VM mice were implanted s.c with 
the VM-M3/Fluc tumor on Day 0. Mice were fasted for 18 hours on Day 3 and 
diet was initiated at Day 4. When control (SD-UR) groups showed signs of 
morbidity, such as lethargy and sudden body weight loss, all mice were 
terminated (Figure 11). Restricted mice received 40-60% less food compared to 
unrestricted groups, and reached 18% of their initial body weights 2-3 days after 
diet initiation. Unrestricted groups returned to their initial body weight 2-3 days 
after diet initiation (Figure 12A). Restriction of Standard Diet (SD-R) and 
KetoGen Diet (KG-R) equally decreased blood glucose significantly compared to 
their unrestricted counterparts (SD-UR, KG-UR) at p<0.05 (Figure 12B). SD-R, 
KG-UR and KG-R groups had significantly higher β-hydroxybutyrate levels 
compared to control SD-UR group at p<0.05. Also KG-R group had significantly 
higher β-hydroxybutyrate values compared to SD-R and KG-UR groups at 
p<0.01 (Figure 12C). Glucose ketone index (GKI) was calculated as described in 
materials and methods. KG-R group had significantly lower GKI compared to all 
other groups at p<0.01 (Figure 12D). 
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Primary tumor growth was significantly lower in SD-R, KG-UR and KG-R 
compared to control (SD-UR) group at p<0.01. Also KG-R group had significantly 
lower primary tumor weight compared to SD-R and KG-UR groups at p<0.05 
(Figure 13, 14). KG-R group had significantly lower metastasis to liver, lung, 
spleen and kidney compared to SD-UR and SD-R groups at p<0.05. However, 
SD-R or KG-UR groups did not reduce the metastasis to organs compared to 
control SD-UR mice (Figure 15). KG-R group also had significantly lower 
metastasis to brain compared to SD-UR group at p<0.05 (Figure 16). 
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Figure 11. Experimental design for the analysis of diet influence on VM-
M3/Fluc flank tumor growth and metastasis. VM mice were implanted s.c. with 
the VM-M3/Fluc tumor as explained in Materials and Methods. Mice were fasted 
for 18 hours on Day 3 before the initiation of the diet on Day 4. Mice were fed 
either with unrestricted Standard Diet (SD-UR), restricted Standard Diet (SD-R), 
unrestricted KetoGen diet (KG-UR) or restricted KetoGen diet (KG-R). All mice 
were imaged in vivo, organs and tumors collected and imaged ex vivo at the time 
of termination. 
  
	   71	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  Day	  0 
Implant	  	  tumor	  s.c 
Day	  3 
18hr	  fast 
Day	  19-­‐25 
Terminate	  all	  groups 
Image	  &	  collect organs	  and	  tumors 
Implement Diet 
Day	  4 	   	   	  
Experimental	  Groups	  	  	  (N	  =	  8	  /	  all	  groups): Standard	  Diet	  Unrestricted	  (SD-­‐UR) Standard	  Diet	  Restricted	  (SD-­‐R)	  (18%	  body	  weight	  reduction) KetoGen	  Unrestricted	  	  (KG-­‐UR) KetoGen	  Restricted	  (KG-­‐R)	  (18%	  body	  weight	  reduction) 
	   72	  
Figure 12. Influence of diet on body weight, blood glucose and β-
hydroxybutyrate levels of VM-M3/fluc subcutaneous tumor bearing mice. 
Mice were fed either with unrestricted Standard Diet (SD-UR), restricted 
Standard Diet (SD-R), unrestricted KetoGen diet (KG-UR) or restricted KetoGen 
diet (KG-R). (A)  Restricted groups received 40-60% less food in order to reach 
18% body weight reduction. Body weights were monitored daily. Prior to 
treatment, the body weights of all mice were averaged for a single value. Values 
represent the average ± standard error of the mean (SEM). Mice were sacrificed 
20–25 days post-implantation and blood was collected for the analysis of (B) 
glucose and (C) β-hydroxybutyrate (D) Glucose Ketone Index levels, as 
explained in Materials and Methods. All data is represented as mean ± standard 
error of the mean (SEM). Single asterisk indicates that values are significantly 
different compared to control (SD-UR) group at p < 0.05. Double asterisk 
indicates that KG-R values are significantly different than SD-UR, SD-R and KG-
UR values at p < 0.01.   
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Figure 13. Influence of restricted ketogenic diet on subcutaneous growth of 
VM-M3/Fluc tumor. Representative images of tumor bearing mice either fed with 
unrestricted standard diet (SD-UR) or restricted KetoGen Diet (KG-R). VM mice 
implanted s.c. with VM-M3/Fluc tumor. Pictures were taken 25 days after 
implantation. 
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Figure 14. Influence of diet on primary tumor weight of VM-M3/Fluc 
subcutaneous tumor. VM mice were either fed with unrestricted Standard Diet 
(SD-UR), restricted Standard Diet (SD-R), unrestricted KetoGen diet (KG-UR) or 
restricted KetoGen diet (KG-R). All values are represented as mean ± SEM. 
Single asterisk indicates that values are significantly different than the control 
(SD-UR) group at p<0.01. Double Asterisk indicates that KG-R values are 
significantly different than SD-UR, SD-R and KG-UR groups at p<0.05. 
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Figure 15. Influence of diet on distant organ metastasis of VM-M3/fluc 
tumor. VM mice were fed either with unrestricted Standard Diet (SD-UR), 
restricted Standard Diet (SD-R), unrestricted KetoGen diet (KG-UR) or restricted 
KetoGen diet (KG-R). At the time of sacrifice, the organs were removed and 
imaged ex vivo. Bioluminescence values were plotted on a log scale. All values 
represent the average ± SEM. Asterisk indicates that KG-R values are 
significantly different than SD-UR and SD-R groups at p<0.05. 
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Figure 16. Influence of diet on brain metastasis of VM-M3/fluc tumor. VM 
mice were fed either with unrestricted Standard Diet (SD-UR), or restricted 
KetoGen diet (KG-R). (A) Representative images of VM-M3 tumor brain 
metastasis with SD-UR and KG-R feeding. Images were taken in vivo 10 minutes 
after i.p luciferin injection. Whole body was covered with black masking paper to 
prevent the bioluminescence contribution from primary tumor.  (B) At the time of 
sacrifice, the brains were removed and imaged ex vivo. All values represent the 
average ± SEM. Asterisk indicates that KG-R values are significantly different 
than SD-UR group at p<0.05. 
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Influence of diet on survival of VM-M3/Fluc subcutaneous tumor bearing 
mouse  	  
In this experiment we analyzed whether calorie restriction and/or ketogenic diet 
can increase VM-M3 tumor bearing mouse survival. VM mice were implanted s.c 
with the VM-M3/Fluc tumor on Day 0. Mice were fasted for 18 hours on Day 3 
and diet (SD-UR, SD-R, KG-UR or KG-R) was initiated at Day 4. Mice were 
euthanized individually when they showed signs of morbidity, such as lethargy 
and sudden body weight loss (Figure 17). Restricted groups (SD-R, KG-R) 
reached 18% of their initial body weights (Figure 18A, 18B) and had significantly 
lower blood glucose compared to unrestricted groups (SD-UR, KG-UR) at 
p<0.05. KG-R group had significantly higher ketone values compared to all other 
groups, and had lowest GKI values at p<0.01 (Figure 18C, 18D). Primary tumor 
volume was significantly lower in SD-R, KG-UR and KG-R compared to control 
(SD-UR) group at p<0.05. Also KG-R group had significantly lower primary tumor 
volume compared to SD-R and KG-UR groups at p<0.05 (Figure 19) 
All control group (SD-UR) mice reached morbidity 17-22 days post implantation. 
KG-R group survived longer compared to SD-R and KG-UR groups at p<0.05 
(Figure 20). 
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Figure 17. Experimental Design for the diet influence on survival of VM-
M3/Fluc subcutaneous tumor bearing mouse  
VM mice were implanted s.c. with the VM-M3/Fluc tumor as explained in 
Materials and Methods. Mice were fasted for 18 hours on Day 3 before the 
initiation of the diet on Day 4. Mice were fed either with unrestricted Standard 
Diet (SD-UR), restricted Standard Diet (SD-R), unrestricted KetoGen diet (KG-
UR) or restricted KetoGen diet (KG-R). Tumor volumes were measured with 
Caliper on Day 14. Mice with clear signs of morbidity such as lethargy and heavy 
breathing were euthanized throughout the study. Study terminated with the 
euthanization of last mice on Day 37. 
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Figure 18. Influence of diet on body weight, blood glucose and β-
hydroxybutyrate levels of VM-M3/fluc tumor bearing mice (A) Mice were fed 
either with unrestricted Standard Diet (SD-UR), restricted Standard Diet (SD-R), 
unrestricted KetoGen diet (KG-UR) or restricted KetoGen diet (KG-R). Restricted 
groups received 40-60% less food in order to reach 18% body weight reduction.  
Body weights were monitored daily. Prior to treatment, the body weights of all 
mice were averaged for a single value. Values represent the average ± standard 
error of the mean (SEM). Body weights are not plotted after day 22, due to the 
decrease in number of animals.  Blood was collected for the analysis of (B) 
glucose and (C) β-hydroxybutyrate (D) Glucose Ketone Index levels as explained 
in Materials and Methods. All data is represented as mean ± standard error of the 
mean (SEM). Single asterisk indicates that values are significantly different 
compared to control (SD-UR) group at p < 0.05. Double asterisk indicates that 
KG-R values are significantly different than SD-UR, SD-R and KG-UR values at p 
< 0.01.  
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Figure 19. Influence of diet on primary tumor volume of subcutaneous VM-
M3/Fluc tumor growth. VM mice were  fed either with unrestricted Standard 
Diet (SD-UR), restricted Standard Diet (SD-R), unrestricted KetoGen diet (KG-
UR) or restricted KetoGen diet (KG-R). Tumor volumes were measured with 
digital caliper and volumes calculated as V= (length × Width2)/2. All values are 
represented as mean ± SEM. The asterisk indicates that values are significantly 
different than the control (SD-UR) group at p < 0.05. Double Asterisk indicates 
that KG-R values are significantly different than SD-UR, SD-R and KG-UR 
groups at p < 0.05. 
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Figure 20. Influence of diet on the survival of VM-M3/fluc tumor bearing 
mice. VM mice were fed either with unrestricted Standard Diet (SD-UR), 
restricted Standard Diet (SD-R), unrestricted KetoGen diet (KG-UR) or restricted 
KetoGen diet (KG-R). VM mice were implanted with the VM-M3/Fluc tumor as 
described in Materials and Methods.17-25 days after tumor implantation, SD-UR 
(control) groups mice reached morbidity. Asterisk indicates that KG-R grouped 
survived significantly longer than SD-UR, SD-R and KG-UR groups at p<0.05.  
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Influence of diet on intracranial growth and contra-lateral invasion of VM-
M3/Fluc brain tumor 
VM-M3 tumor was originally identified in the brain and shows all the 
characteristics of glioblastoma multiforme including invasion to the contralateral 
side of the brain. Therefore we analyzed the effect of diet on VM-M3 tumor 
growth in brain and contralateral invasion. 1 mm3 of VM-M3/Fluc tumor tissue 
pieces were implanted into right hemisphere of VM mice on Day 0. Mice were 
fasted for 18 hours on Day 3 and diet (SD-UR, SD-R, KG-UR or KG-R) was 
initiated at Day 4 (Figure 21). In correlation with previous experiments, KG-R 
delivered the lowest GKI values with significantly higher ketone values at p<0.05 
(Figure 22).  At Day 15, removed brains were dissected into ipsi-lateral and 
contra-lateral hemispheres and imaged ex-vivo as represented in Figure 23. 
Whole brain bioluminescence represents sum of ipsi-lateral and contra-lateral 
hemispheres. KG-R group had significantly lower whole brain bioluminescence 
compared to SD-UR and SD-R groups at p<0.05 (Figure 24A). Contra-lateral 
invasion was measured by the bioluminescence light coming from contra-lateral 
brain hemisphere. KG-R had significantly lower contra-lateral invasion compared 
to all the other groups at p<0.05 (Figure 24B). 
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Figure 21. Experimental design for the analysis of diet influence on 
intracranial growth and contra-lateral invasion of VM-M3/Fluc brain tumor. 
VM mice were implanted i.c with the VM-M3/Fluc tumor as explained in Materials 
and Methods. Mice were fasted for 18 hours on Day 3 before the initiation of the 
diet on Day 4. Mice were fed either with unrestricted Standard Diet (SD-UR), 
restricted Standard Diet (SD-R), unrestricted KetoGen diet (KG-UR) or restricted 
KetoGen diet (KG-R). All mice are imaged in vivo, brains collected and imaged 
ex vivo at time of termination. 
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Figure 22. Influence of diet on body weight, blood glucose and β-
hydroxybutyrate levels of VM-M3/fluc brain tumor bearing mice. (A) Mice 
were fed either with unrestricted Standard Diet (SD-UR), restricted Standard Diet 
(SD-R), unrestricted KetoGen diet (KG-UR) or restricted KetoGen diet (KG-R). 
Restricted groups received 40-60% less food in order to reach 18% body weight 
reduction.  Body weights were monitored daily. Prior to treatment, the body 
weights of all mice were averaged for a single value. Values represent the 
average ± standard error of the mean (SEM). Mice were sacrificed 14 days post-
implantation and blood was collected for the analysis of (B) glucose and (C) β-
hydroxybutyrate (D) Glucose Ketone Index levels as explained in Materials and 
Methods. All data is represented as mean ± standard error of the mean (SEM). 
Single asterisk indicates that values are significantly different compared to 
control (SD-UR) group at p < 0.05. Double asterisk indicates that KG-R values 
are significantly different than SD-UR, SD-R and KG-UR values at p < 0.05.  
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Figure 23. Bioluminescent imaging of VM-M3/Fluc tumor growth in VM 
mouse brain. (A) 1 mm3 of VM-M3/Fluc tumor tissue pieces were implanted into 
right hemisphere of VM mice. At Day 15, Removed brains were dissected into 
ipsi-lateral and contra-lateral hemispheres.  (B) Bioluminescence images were 
taken with Xenogen Imaging system. Representative images are shown. 
 
  
	   97	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contra-­‐lateral Ipsi-­‐lateral 
Tumor	  Implantation A 
B 
	   98	  
Figure 24. Influence of diet on intracranial growth and contra-lateral 
invasion of VM-M3/Fluc brain tumor. VM mice were fed with either unrestricted 
Standard Diet (SD-UR), restricted Standard Diet (SD-R), unrestricted KetoGen 
diet (KG-UR) or restricted KetoGen diet (KG-R). Brains were removed 14 days 
after tumor implantation and were dissected to ipsi-lateral and contra-lateral 
hemispheres. Bioluminescence images were taken with Xenogen Imaging 
system. (A) Whole brain bioluminescence (sum of ipsi-lateral and contra-lateral 
hemispheres) (B) Contra-lateral hemisphere bioluminescence. Values are 
expressed as mean ± standard error of the mean (SEM). Asterisk indicates that 
values are significantly different compared to control (SD-UR) group at p < 0.05 
  
	   99	  
 
 
 
N = 12 / all groups 
 
 
 
 
 
 
 
0	  10	  
20	  30	  
40	  50	  
60	  70	  
80	  90	  
100	  
SD-­‐UR	   SD-­‐R	   KG-­‐UR	   KG-­‐R	  
W
ho
le
	  b
ra
in
	  
bi
ol
um
in
es
ce
nc
e	  
(p
ho
to
ns
/s
ec
)	   x	  1
00
00
0	  
A 
B 
0	  
5	  
10	  
15	  
20	  
SD-­‐UR	   SD-­‐R	   KG-­‐UR	   KG-­‐R	  
Co
nt
ra
-­‐la
te
ra
l	  
bi
ol
um
in
es
ce
nc
e	  
(p
ho
to
ns
/s
ec
)	  
x	  
10
00
00
	  
*	  
	  *	  
	   100	  
 
Influence of KetoGen ketogenic diet vs KetoCal ketogenic diet on growth 
and metastatic spread of VM-M3/fluc subcutaneous tumor 
In this experiment we analyzed whether restricted feeding of different brand 
ketogenic diets would have similar effect on VM-M3 tumor growth and 
metastasis. VM mice were implanted s.c with the VM-M3/Fluc tumor on Day 0. 
Mice were fasted for 18 hours on Day 3 before diet initiation at Day 4 (Figure 25). 
The mice were fed either with KetoCal ketogenic diet (Nutricia LLC) or KetoGen 
ketogenic diet (Solace Nutrition LLC) in restricted amounts, in order to reach 18% 
body weight reduction. Body weights of KC-R and KG-R mice were similar 
throughout the study (Figure 26A). However, in KG-R group, blood glucose levels 
were significantly lower and β-hydroxybutyrate levels were significantly higher 
compared to KC-R group at p < 0.05 (Figure 26B, 26C). Therefore KG-R groups 
had significantly lower GKI values compared to KC-R group (Figure 26D). 
Restricted feeding of KetoGen ketogenic diet (KG-R) significantly lowered 
primary VM-M3 tumor growth compared to restricted feeding of KetoCal 
ketogenic diet (KC-R) at p<0.01 (Figure 27). KG-R also significantly lowered VM-
M3 tumor metastasis to liver, lung, spleen and kidney compared to KC-R at 
p<0.05 (Figure 28). 
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Figure 25. Experimental design for the analysis of KetoGen and KetoCal 
ketogenic diet influence on VM-M3/Fluc growth and metastasis. . VM mice 
were implanted s.c. with the VM-M3/Fluc tumor as explained in Materials and 
Methods. Mice were fasted for 18 hours on Day 3 before the initiation of the diet 
on Day 4. VM mice were fed either with restricted KetoGen diet (KetoGen-R) or 
restricted KetoCal (KetoCal-R). All mice were imaged in vivo, organs and tumors 
collected and imaged ex vivo at time of termination. 
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Figure 26. Influence of restricted KetoGen and KetoCal ketogenic diet on 
body weight, blood glucose and β-hydroxybutyrate levels of VM-M3/Fluc 
subcutaneous tumor bearing VM mice. (A) VM mice were fed either with 
restricted KetoGen diet (KetoGen-R) or restricted KetoCal (KetoCal-R).  
Restricted groups received 40-60% of daily food intake in order to reach 18% 
body weight reduction.  Body weights were monitored daily. Prior to treatment, 
the body weights of all mice were averaged for a single value. Values represent 
the average ± standard error of the mean (SEM). Mice were sacrificed 20–25 
days post-implantation and blood was collected for the analysis of (B) glucose 
and (C) β-hydroxybutyrate (D) Glucose Ketone Index levels, as explained in 
materials and methods. All data is represented as mean ± standard error of the 
mean (SEM). Asterisk indicates KetoGen feeding significantly reduced blood 
glucose levels and increased β-hydroxybutyrate level compared to restricted 
KetoCal feeding that at p < 0.05.   
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Figure 27. Influence of restricted KetoGen and KetoCal diet on primary VM-
M3 tumor growth. VM mice were fed either with restricted KetoGen diet 
(KetoGen-R) or restricted KetoCal (KetoCal-R). All values are represented as 
mean ± SEM. The asterisk indicates that restricted KetoGen feeding reduced 
VM-M3/Fluc tumor growth significantly at p<0.01 compared to restricted KetoCal 
feeding. 
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Figure 28. Influence of restricted KetoGen and KetoCal diet on distant 
organ metastasis of VM-M3/Fluc tumor. VM mice were fed either with 
restricted KetoGen diet (KetoGen-R) or restricted KetoCal (KetoCal-R). All values 
are represented as mean ± SEM. The asterisk indicates that restricted KetoGen 
feeding reduced VM-M3/Fluc tumor growth significantly compared to restricted 
KetoCal feeding. At the time of sacrifice, the organs were removed and imaged 
ex vivo. Bioluminescence values were plotted on a log scale. All values represent 
the average ± SEM. The asterisk indicates that restricted KetoGen feeding 
reduced organ metastasis significantly at p<0.05 compared to restricted KetoCal 
feeding. 
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Influence of diet on CL, BMP and PG amount of VM-M3 tumor tissues 	  
It has been shown that BMP increases in starved cells, due to increased 
autophagy. CL is an essential component for respiration in mitocohondria and CL  
abnormalities found in many tumor cell types. Therefore we were interested in 
BMP and  CL, and their precursor PG levels in VM-M3 tumor cells under different 
diet conditions. Acidic lipids were analyzed from VM-M3 tumor tissues fed with 
unrestricted Standard Diet (SD-UR), restricted Standard Diet (SD-R), unrestricted 
KetoGen diet (KG-UR) or restricted KetoGen diet (KG-R). CL, BMP and PG were 
significantly higher in KetoGen fed animals (KG-UR, KG-R) compared to control 
animals (SD-UR) at p< 0.05 (Figure 29, Table 6). 
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Figure 29. Influence of diets on acidic lipids of VM-M3 subcutaneous tumor. 
Mice were fed either with unrestricted Standard Diet (SD-UR), restricted 
Standard Diet (SD-R), unrestricted KetoGen diet (KG-UR) and restricted 
KetoGen diet (KG-R). Tumors were collected at the end of study and lipids were 
isolated as described in Materials and Methods in Chapter 1. Plate was 
developed to a height of 6.0 cm with chloroform: methanol: acetic acid: formic 
acid: water (70:30:12:4:2 by volume), and developed to the top with hexanes: 
diisopropyl ether: acetic acid (65:35:2 by volume). The amount of acidic lipids 
spotted on the HPTLC for each cell line was equivalent to 600 µg of cell dry 
weight, FFA, free fatty acid; IS, internal standard; CL, cardiolipin; PA, 
phosphatidic acid; PG, PhosphatidylGlycerol; PS, phosphatidylserine; and PI, 
phosphatidylinositol. 	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Table	  6:	  Influence	  of	  diet	  on	  acidic	  lipids	  of	  VM-­‐M3	  tumor	  tissue	  
	   	   	   	   	   	   	   	   	   	   	   	   	  
	  
SD-­‐UR	   SD-­‐R	   KG-­‐UR	   KG-­‐R	  
Acidic	  Lipids	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
CL	   127.2	   ±	   6.9	   142.9	   ±	   10.2	   192.4	   ±	   3.3*	   165.2	   ±	   5.6*	  
BMP	   99.9	   ±	   7.2	   125.6	   ±	   8.1	   162.1	   ±	   8.3*	   165.9	   ±	   7*	  
PG	   113.5	   ±	   8.1	   118.6	   ±	   9.3	   155.0	   ±	   11.1*	   153.6	   ±	   9.1*	  
PS	   264.0	   ±	   21.3	   287.8	   ±	   17.0	   283.6	   ±	   4.8	   262.9	   ±	   20.6	  
PI	   246.8	   ±	   16.5	   266.3	   ±	   21.5	   260.8	   ±	   19.5	   235.5	   ±	   16.5	  
*	  Significantly	  different	  than	  SD-­‐UR	  and	  SD-­‐R	  values	  at	  p<	  0.05	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Composition of Standard Diet and KetoGen ketogenic diet (KG) and 
KetoCal® ketogenic diet (KC) 
 
As seen in Table 7, standard diet includes higher carbohydrate amounts (62 g) 
compared to KetoGen (2.54g) and KetoCal (8.8g) ketogenic diets for every 100g 
of the complete formula. Standard diet has lower fat amounts (6g) compared to 
KetoGen (74g) and KetoCal (69.1g) ketogenic diets. Also, KetoGen ketogenic 
diet has lower carbohydrate (2.54g vs 8.8g) and higher fat amounts (74g vs 
69.1g) compared to KetoCal ketogenic diet. 
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Table 7: Composition of Standard Diet and KetoGen ketogenic diet and 
KetoCal® ketogenic diet 
Components 
Standard Diet 
(SD) 
KetoGen 
(KG) 
KetoCal Diet  
(KC) 
    Carbohydrate * 62 2.54 8.8 
Fat * 6 74 69.1 
Protein * 27 15.17 14.4 
Energy (Kcal/gr) 4 6.9 7.2 
Fat/(Protein+Carbohydrate) 0.07 4.17 3 
  	   	  
*Values are presented as g/100g diet 
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Discussion 
 
Cancer is the second leading cause of death in United States after heart disease 
and cancer kills more people than heart disease in every age group other than 
65+ according to National Center for Health statistics report on 2013. Despite 
years of extensive research, little accomplishment has been achieved on cancer 
treatments [199]. Most conventional therapies, such as radiation and 
chemotherapy, are extremely toxic and these therapies do not target tumor cells 
specifically, which also causes damage to normal cells and tissues [200]. Since 
all cancers suffer from an abnormal metabolism, therapeutic strategies that focus 
on cancer metabolism promise effectiveness with reduced adverse effects on 
normal cells and tissues [201].  
 
Cancer cells generate ATP mainly through glucose fermentation due to their 
mitochondrial abnormalities [141]. Non-toxic metabolic therapies can exploit the 
cancer cell mitochondria defects, while protecting normal cells [151, 202]. Calorie 
restriction or ketogenic diets can reduce the glucose available to cancer cells, 
while providing ketones as an alternative fuel that can only be metabolized 
efficiently by normal cells [184]. Low carbohydrate, high fat ketogenic diets are 
previously used safely and successfully in humans, for treatment of epilepsy and 
also cancer [203-206]. Seyfried and his colleagues showed that KetoCal 
ketogenic diet reduced primary tumor growth of mouse CT2A glioma in B6 
mouse as well as U87 human tumor growth in SCID mouse [207]. However, in 
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these studies, restricted KetoCal ketogenic feeding did not reduce tumors 
compared to calorie matched restricted standard diet counterparts [207]. In other 
words, restriction was the primary reason of therapeutics, but not the type of diet. 
In these studies, calorie restriction decreased blood glucose and increased 
ketone levels compared to unrestricted feeding, and tumor growth directly 
correlated with reduced blood glucose levels. Authors also observed a slight 
increase in body weight and blood glucose in animals fed with unrestricted 
KetoCal ketogenic diet. Therefore, Seyfried et al overemphasized the importance 
of calorie restriction for tumor management, since feeding with unrestricted 
KetoCal ketogenic diet can increase blood glucose levels and can cause insulin 
insensitivity [151, 208]. Reduced availability of glucose as the primary fuel for 
cancer cells cause an energy restriction to tumor cells, and reduce their 
proliferative capabilities. However, therapeutic effect of calorie restriction on 
primary tumors does not only result from the decreased metabolite availability, 
but it is also a result of the down regulation of growth pathways such as 
PI3K/Akt, decrease in inflammation and angiogenesis in the tumor environment 
[168-172].  
 
In this work, I analyzed the growth and metastasis of VM-M3 cells under 
Standard diet or KetoGen ketogenic diet (Solace Nutrition LLC) feeding, in 
unrestricted or restricted conditions.  Calorie restriction of a standard diet (SD-R) 
group significantly decreased VM-M3/Fluc primary tumor growth when compared 
to unrestricted SD-UR control group as previously shown by Shelton et al (Figure 
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14) [209]. SD-R group had significantly lower blood glucose levels and higher 
ketone values compared to SD-UR group (Figure 12). However, calorie 
restriction did not decrease metastasis to organs liver, lungs, spleen and kidneys 
(Figure 15). On the other hand, it significantly increased the survival rate of VM-
M3 tumor bearing animals [209]. Positive effects of calorie restriction on tumor 
bearing mice survival might result from other health benefits obtained from 
calorie restrictions, such as reduction of systemic inflammation [210]. Also In SD-
UR fed tumor bearing animals, tumors reach to considerable sizes (2-3 grams) 
towards the end of study (Figure 14). Tumor cells need high amounts of fuel to 
maintain their viability and cause systemic protein breakdown, known as cancer 
cachexia. Therefore, high tumor burden in SD-UR group, might also be 
contributing to the worse prognosis seen in this group. 
 
Restricted KetoGen feeding (KG-R) decreased the tumor growth significantly 
when compared to SD-UR, SD-R and KG-UR groups (Figure 14). KG-R had 
similar blood glucose levels to SD-R group suggesting that blood glucose might 
not be the only predictor for primary tumor growth (Figure 12). In fact, ketones 
were significantly higher (up to 3 fold) in KG-R group compared to SD-UR, SD-R 
and KG-UR groups, supporting the tumor reducing capabilities of ketones (Figure 
12). KG-R delivered lowest GKI values and suggests that Glucose Ketone Index 
(GKI) values could be efficiently used to assess the efficacy of metabolic 
therapies on primary tumor growth (Figure 12). KG-R group had also significantly 
lower metastasis to liver, lungs, spleen and kidneys compared to SD-UR and SD-
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R groups (Figure 15). KG-R group also survived significantly longer compared to 
SD-UR, SD-R and KG-UR groups (Figure 20). These results showed that 
restricted feeding of KetoGen ketogenic diet (KG-R) delivered better therapeutic 
effect compared to restricted feeding of standard diet (SD-R). Since KG-R group 
had lower GKI values compared all other groups in these studies, GKI values 
possibly can be used to assess the effect of metabolic treatments on metastasis 
and overall survival (Figure 18D). 
 
Animals fed with unrestricted ketogenic diet (KG-UR) had similar body weights 
when compared to animals fed with unrestricted standard diet (SD-UR) (Figure 
12A,18A). However, in some occasions, slight body weight reductions were 
observed with KG-UR feeding if initial mouse body weight was higher than 30g 
(Figure 18A). KG-UR feeding did not decrease blood glucose levels when 
compared to unrestricted feeding of standard diet (SD-UR) (Figure 12B,18B), but 
it increased β-hydroxybutyrate levels compared to SD-UR group (Figure 
12C,18C). Therefore KG-UR had lower GKI levels compared to SD-UR group 
(Figure 12D,18D). These results further suggests that blood glucose is not the 
only predictor of tumor growth, but lower GKI values can predict the therapeutic 
potential of dietary treatments.  
 
I also evaluated the effect of diet on growth of VM-M3 tumor in brain of VM mice, 
and also on contra-lateral invasion. Shelton et al demonstrated that VM-M3 brain 
tumor shows all characteristics of the Glioblastoma Multiforme (GBM) and it can 
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be used to evaluate rapid therapeutic strategies for this invasive and deadly 
tumor type[110]. Restricted KetoGen diet effectively reduced the overall VM-
M3/Fluc tumor growth in brain of VM mice compared to SD-UR and SD-R groups 
(Figure 24A). VM-M3 tumor cells also showed lower invasion to contra-lateral site 
of the brain in KG-R group suggesting this diet was also effective against highly 
invasive VM-M3 brain tumor (Figure 24B). 
 
Previously it has ben shown that unrestricted KetoCal ketogenic diet did not have 
tumor reducing effect on on CT2A and U87 brain tumors [207]. In addition, 
unrestricted feeding of KetoCal ketogenic diet increased body weight of VM 
mouse, increased VM-M3 tumor growth and metastasis (unpublished observation 
by Shelton LM). However in these studies we found that unrestricted KetoGen 
ketogenic diet (KG-UR) reduced both flank and brain VM-M3 tumor growth and 
significantly prolonged survival compared to SD-UR group (Figure 14,20,24). 
Therefore, I compared the effect of different brand ketogenic diets, KetoGen and 
KetoCal, on VM-M3 tumor growth and metastasis. In order to eliminate possible 
body weight differences with unrestricted feeding, both diets were given in 
restricted amounts in order to reach 18% body weight reduction (Figure 26A). 
Ketogen restricted (KG-R) group had significantly lower tumor growth and 
metastasis compared to KetoCal-restricted (KC-R) group (Figure 27,28). These 
results suggested that all ketogenic diets might not deliver the same therapeutic 
effect on tumor growth and metastasis. KG-R fed animals also had significantly 
lower glucose levels, higher ketone levels and lower GKI ratio compared to KC-R 
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animals (Figure 26B,C,D). These observations suggest that effective metabolic 
therapy for the treatment of tumor growth and metastasis results from both 
increased ketones and decreased glucose levels. 
 
Ketones, mainly β-hydroxybutyrate, can only generate ATP through oxidative 
phosphorylation, and cannot be metabolized efficiently in cancer cells with 
abnormal metabolism [211]. Also enzymes that are needed for ketone utilization, 
such as β-hydroxybutyrate dehydrogenase (β -OHBDH), and succinyl-CoA: 3-
ketoacid CoA transfer (SCOT) expressions are altered in many types of cancer 
cells [184, 186, 212-214]. However, our results suggest that ketones also have 
anti-tumor effects rather than simple absence of utilization, since elevation of 
ketones reduces tumor growth and metastasis. Recently, Poff et al showed that 
ketones inhibit the growth of VM-M3 cells in vitro, and ketone supplementation 
inhibited VM-M3 organ metastasis, suggesting a direct therapeutic effect of 
ketones on tumor growth and metastasis [215].  
 
Cardiolipin content and structure is crucial for mitochondrial function and its 
efficient respiration. Kiebish et al observed cardiolipin content and fatty acid 
profile is altered in tumor tissues compared to normal tissues [107]. We observed 
that cardiolipin content was higher in tumor cells in ketogenic diet groups (KG-
UR, KG-R) compared to control (SD-UR) group (Figure 29,Table 6). Ketones get 
converted to Acetyl-Coa and enter mitochondria directly, and cannot be 
metabolized to lactate as glucose [175]. Ketones might force cancer cells to 
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oxidative phosphorylation and might be cause an increase in cardiolipin content 
and/or remodeling of the CL fatty acid species, i.e. mitochondrial biogenesis. It 
needs to be further investigated however, if this mitochondrial biogenesis can 
rescue the cancer phenotype, and revert uncontrolled proliferation of tumor cells. 
Warburg stated that respiratory insufficiency in cancer cells becomes eventually 
irreversible [141]. If respiration damage in cancer cells is irreversible, forcing 
cancer cells to use oxidative phosphorylation might cause an increased electron 
leak, and more ROS formation, and eventually death of the cancer cells.  Bonnet 
et al showed that Dichloroacetate (DCA), shifts metabolism from glycolysis to 
glucose oxidation, increases mitochondrial ROS and eventually causes cancer 
cell death [216]. This mechanism might explain why ketogenic diet increased the 
efficacy of ROS generating cancer therapies such as radiation and hyperbaric 
oxygen therapies[188, 189, 191]. Cancer cells cannot cope with excessive ROS 
levels beyond their capacity, and detrimental oxidative stress can lead to cell 
death. Reduced glucose can limit the anti-oxidant capabilities of tumor cells due 
to decreased NADPH generation by down regulation of pentose phosphate 
pathway and additional ROS generation can cause cancer cell death [157]. 
 
BMP content is increased in serum-starved cells as a result of nutrient stress and 
autophagy, the process where cells degrade its own materials [5, 217]. I 
observed that BMP increased in tumor tissues with restricted feeding of standard 
diet (SD-R) compared to control (SD-UR) group (Figure 29, Table 6). Also, BMP 
was even further increased in tumor tissues from ketogenic diet groups (KG-UR 
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and KG-R) and this increase was significant compared to control (SD-UR) 
tumors. These results might suggest that ketogenic diet feeding might cause 
further nutrient stress and autophagy in tumor cells.  
 
Damaged mitochondria is recycled in lysosomal machinery by a different 
autophagy mechanism, called mitophagy. A successful mitophagy is necessary 
for clearing the defective mitochondria and an efficient respiration. CL level 
increase observed in VM-M3 tumor cells with ketogenic diet might be resulted 
from increased CL synthesis with mitocohondria utilization increase with ketones, 
or an increased clearance of defective mitochondria. Degradation of CL can be 
the result to an increase PG, which is the precursor for BMP. It has been 
previously shown that CL is not the precursor for BMP synthesis. However, 
elevation of CL, PG and BMP in VM-M3 tumor cells with ketogenic diet feeding 
brings a question whether there is a crosstalk between these lipids. Even though 
CL might not be a precursor for BMP in de novo synthesis, in certain situations 
such as CL degradation in lysosomes with mitophagy, PG can be abundant in 
lysosomes and can be directly used for BMP synthesis. These questions need 
further research to be answered. 
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CONCLUSIONS 
 
 
In this thesis work, First I observed a dramatic increase of BMP levels in GM1 
and GM2 gangliosidoses brain samples in humans, American black bear, cats, 
and mice compared to their non-diseased counterparts. BMP have functional 
roles in endo-lysosomal system such as formation, structure, and trafficking of 
endosomal/lysosomal compartments. BMP facilitates the degradation of 
glycosphingolipids in the limiting membrane of endosomal and lysosomal 
compartments. BMP also plays roles in many pathological conditions such as 
atherogenesis, viral infection and lysosomal storage diseases and modulating 
BMP levels can alleviate the pathologies observed in these diseases. Lysosomal 
storage diseases also involve inflammation. Within the discovery of BMP as a 
macrophage associated lipid, it was very important to evaluate the reason for 
BMP storage in gangliosidosis in relation to inflammation. In this regard, I found 
evidence suggesting BMP stored in gangliosidoses as a consequence of the 
primary stored gangliosides rather than being an inflammation associated 
phenomena. We hope that the information presented in this thesis could be 
helpful in future studies that evaluate BMP synthesis and function. 
 
I also found that macrophage/microglia originated cells with different tissue of 
origins had significantly higher BMP content compared to non-macrophage cell 
lines. Macrophages are important players of immune response and they play 
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either a direct role in pathology of many diseases such as atheroschlerosis, HIV 
infection and cancer. Therefore this discovery is of utmost importance for 
understanding the role of BMP, and its possible contributions to disease 
pathology. 
 
 
In this thesis work, I also found that restricted KetoGen ketogenic feeding (KG-R) 
decreased the VM-M3 tumor growth, metastasis to liver, lungs, spleen and 
kidneys when compared to control (SD-UR) group. VM-M3 tumor bearing mice 
survived significantly longer in KG-R group compared to SD-UR, SD-R and KG-
UR groups. Shelton et al showed that VM-M3 tumor is a pre-clinical model for 
GBM since it shows all the characteristics of growth and invasive spread when 
injected orthotropic to brain. VM-M3 tumors are also highly metastatic to distant 
organs such as liver, lung and spleen when injected to non-brain regions. It is 
known that the metastatic cancer is the major cause of mortality and morbidity in 
humans. Therefore, therapies that have significantly positive effects on VM-M3 
tumor, are high potential candidates for translating to human cancer therapies, 
especially for GMB and other metastatic cancer types. KetoGen ketogenic diet is 
a non-toxic alternative therapy for VM-M3 tumor growth, invasion and metastasis. 
These results might bring valuable insights for the treatment of highly invasive 
and metastatic cancer types in humans with alternative non-toxic metabolic 
therapies. 
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APPENDIX 
Figure 30. Influence of vitamin and mineral supplementation on growth of 
VM-M3 subcutaneous tumor. VM mice were fed either with unrestricted 
Standard Diet (SD-UR), restricted Standard Diet (SD-R), unrestricted KetoGen 
diet without vitamins and minerals (KG-UR), unrestricted KetoGen diet with 
vitamins and minerals(KG-UR + V/M), restricted KetoGen diet without vitamins 
and minerals (KG-R) and restricted KetoGen diet with vitamins and minerals 
(KG-R+ V/M) . Tumor volumes were measured with digital caliper at Day 12 and 
Day 22 and volumes calculated as V= (length × Width2)/2. SD-UR and SD-R Day 
22 values are not presented due to lack of enough alive mice. All values are 
represented as mean ± SEM. Tumor volumes were slightly higher in restricted 
KetoGen  + vitamins and minerals group (KG-R + v/m) than in KetoGen restricted 
no vitamins and minerals group (KG-R) in measurements taken in Day 12 and 
Day 22. This increase was not statistically significant.	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